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1. Introduction 
1.1 Biology of Cancer 
Cancer is defined as abnormal, independent cell growth which can invade or spread to other 
parts of the body, with defects in the regulatory circuits that govern normal cell proliferation 
and homeostasis. This can affect virtually every cell of the body and therefore more than 100 
forms of the disease exist. Cancer is expected to become the main cause of death worldwide 
in the 21st century, as its prevalence and the associated mortality are rapidly growing. One in 
five men and one in six women will suffer from one kind of cancer in their life, and one in eight 
men and one in eleven women will die of the disease [1]. This increase is attributed to a growing 
and aging population and lifestyle issues that have led to a higher prevalence of main risk 
factors [2], such as smoking, heavy alcohol consumption, obesity, and type 2 diabetes [1]. 
The transition of normal cells to a neoplastic state and development of a malignant tumor state 
is a multistep process [3]. In the course of tumor development, malignant cells can develop the 
capacity of autonomously maintaining cell growth signaling [4]. They can acquire, among 
others, the ability to synthesize stimulatory mitogenic factors or induce neighboring cells to do 
so for them, or they can alter the expression profile and structure of growth signal receptors 
[3]. Another step in carcinogenesis is the impairment of anti-proliferative signaling circuits, 
whereby the cells gain the ability to not be excluded from the proliferative cell cycle such that 
they are not nudged into a quiescent (G0) or post-mitotic state. In addition, neoplastic cells find 
a way to make themselves resistant to cell death by apoptosis, necrosis or autophagy [3]. 
Almost all types of cancer cells are assumed to have mutations, such as loss of pro-apoptotic 
regulators due to p53 tumor suppressor gene modifications or overexpression of anti-apoptotic 
regulators such as the bcl-2 oncogene, allowing them to evade apoptosis. These mutations 
generally lead to autonomous cell growth [3-5]. In mammals, however, healthy cells also 
possess an intrinsic multiplication restriction mechanism in the shape of the telomeres which 
cap the ends of chromosomes. Their erosion during each cell cycle is thought to ultimately 
provoke cell death. For this reason, the maintenance of the telomeres is also a crucial 
prerequisite for tumorigenesis [3]. In addition, a tumor needs to ensure sufficient nutrient and 
oxygen supply and disposal of cell waste by developing the competence to initiate 
neovascularization through triggering an “angiogenic switch” in endothelial cells, a property 
which cells only present during organogenesis under normal circumstances [5].  In order to 
escape from the primary tumor mass and move to a new, nutrient-rich environment, cancer 
cells must also develop the skills of tissue invasion and metastasis [3]. Two emerging 
characteristics that a tumor needs for its growth are firstly the ability to modify its energy 
metabolism in a way to adapt to enhanced cell growth and secondly to escape elimination by 
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the ever-alert immune system [3-5]. It has been found that cancer cells can increase their 
glucose uptake and switch their glucose metabolism to glycolysis even under aerobic 
conditions and working mitochondria (Warburg Effect), which is even emphasized under 
hypoxic conditions often seen in a tumor [6].   
 
1.2 The Tumor Microenvironment 
 
Figure 1 Illustration of the tumor microenvironment adapted from Balkwill et al. 2012 and Hanahan et al. 2000.  
A tumor mass does not only consist of the malignant tumor cells, but also of the surrounding 
cells, the extracellular matrix (ECM) and signaling molecules, altogether forming the “tumor 
microenvironment” (Figure 1) [5]. Endothelial cells, which form the tumor-associated blood 
vessels, are found in the tumor stroma, structurally supported by pericytes or pericyte-like 
fibroblasts. The tumor stroma is also infiltrated by cells of the immune system, which have both 
tumor antagonizing and promoting properties. Inflammatory cells can release signaling 
molecules, such as growth, survival, and proangiogenic factors, and thus support tumor 
angiogenesis, stimulate proliferation and help metastatic dissemination [7]. The predominant 
cell type in the tumor stroma are fibroblasts, which create the structural foundation of a tumor 
by secreting ECM components and enzymes. Fibroblasts within the tumor environment secrete 
diverse mitogenic growth factors and are referred to as cancer-associated fibroblasts (CAFs). 
The tumor stromal cells can derive from pre-existing tissues or they can originate from adjacent 
normal tissue progenitor cells or from bone marrow stem cells [5, 7]. Within the tumor, a close 
collaborative network evolves between cancer cells and their supporting stroma. For a 
successful anti-cancer treatment the tumor as a whole has to be taken into account, including 
its distinct differentiated cells and especially including its microenvironment [3]. 
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1.3 Strategies for Cancer Therapy  
The search for new anticancer drugs and other treatment strategies is a constantly evolving 
field and every year new treatment approaches are being developed. At this point, surgery is 
still the most effective treatment for localized, solid tumors. Almost half of all tumors are also 
treated with radiotherapy (RT), often in a combined therapy concept, which provides highly 
effective treatment also for non-resectable local cancers or metastases [8]. In 1946, a new era 
started with the introduction of the first chemotherapeutic drug into modern oncology, 
mechlorethamine, an alkylating agent. In the following years, various new cytotoxic drugs were 
developed, such as antimetabolites (methotrexate, 5-fluorouracil), antimitotics (vinblastine, 
etoposide, or paclitaxel), or cytotoxic antibiotics (doxorubicin, actinomycin D). In the 1960s, 
new combined treatment protocols were implemented, resulting in greater efficacy without 
reaching the maximum tolerated dose of a single drug. A new age of anticancer therapy began 
in the ´80s and ‘90s, when “targeted cancer therapy” became possible through advances in 
molecular and cell biology, allowing the targeting of specific tumor molecules such as growth 
factors and their receptors, signal transducers, or cytoplasmic proteins. The first clinical trial of 
a monoclonal antibody in 1997, trastuzumab, directed against the mutated HER2/neu receptor 
of breast cancer, paved the way for development of up to 30 different monoclonal antibodies 
approved by the European Medicines Agency (EMA) and/or the U.S. Food and Drug 
Administration (FDA) by 2017. An additional emerging approach is the selective targeting of 
the signaling pathways activated in tumors using small molecules. To date, two categories 
have been developed, selective tyrosine kinase inhibitors such as imatinib (BCR-ABL fusion 
protein, ABL, c-Kit, platelet-dericed growth factor [PDGF] receptor), lapatinib (HER2 and 
epidermal growth factor [EGF] receptors), or sunitinib (vascular endothelial growth factor 
[VEGF] receptor, PDGF receptor, c-Kit) and intracytoplasmic serine/threonine kinase inhibitors 
such as rapamycin (mTOR), vemurafenib (BRAF), or tramentinib (MEK). Most recently, a new 
specific anticancer strategy was developed in the form of immune checkpoint inhibitors. This 
involves the use of monoclonal antibodies directed against surface proteins expressed by 
tumors (anti-programmed cell death protein 1 [anti-PD1]) or T-cell protein receptors (anti-
cytotoxic T-lymphocyte-associated antigen 4 [anti-CTLA4]), which downregulate the native 
immune response against the tumor [9]. 
Another novel and very promising approach in the field of anti-tumoral research is cancer gene 
therapy.   
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1.4 Gene Therapy 
Gene therapy involves the therapeutic transfer of genetic material to the cells of a patient as a 
potential curative or preventive approach for a variety of diseases, such as those for which no 
other sufficient treatment option is available at present. Recently, there has been great 
progress in the area of gene therapy in a large variety of disorders, particularly genetic 
diseases such as primary immunodeficiencies, hemoglobin and coagulation disorders, 
neurological malfunctions, retinal disorders and a variety of cancer types [10]. This has resulted 
in the groundbreaking first EMA approval of the gene therapy products Glybera® (uniQure) for 
treatment of lipoprotein lipase deficiency in 2012 and Strimvelis® (GlaxoSmithKline) for 
adenosine deaminase deficiency (ADA-SCID) in 2016. This was followed in 2018, by the first 
CAR-T cell therapy products Kymriah® (Novartis) and Yescarta® (Gilead) for leukemia and 
lymphoma respectively [11], Luxturna® (Spark Therapeutics) for the treatment of patients 
enduring a loss of vision due to inherited retinal dystrophy, and most recently, in 2019, by 
Zynteglo® for the treatment of beta thalassemia (bluebird bio). 
The field of gene therapy has made considerable strides in the last decade in large part due 
to the development of new vector platforms and an increasing repertoire of therapeutic genes. 
Still, in most of the almost 2600 clinical trials conducted in the field of gene therapy worldwide 
by 2018, one of the biggest obstacles has been the limited amount of genetically modified 
material reaching the site of action resulting in an insufficient therapeutic effect. Therefore, a 
wide range of different gene transfer vehicles are under intensive clinical investigation, ranging 
from different kinds of viruses (adeno-, retro-, or lentivirus) to non-viral vehicles, such as 
lipofection, naked DNA or different kinds of modified cells, such as macrophages, T-cells, or 
stem cells [11, 12]. In addition, a critical element in the design of clinical gene therapy trials is 
the search for opportunities for non-invasive monitoring of the in vivo distribution of viral and 
non-viral vectors, as well as monitoring of the biodistribution, level and duration of transgene 
expression. The sodium iodide symporter (NIS) has emerged as one of the most promising 
reporter and therapy genes available today, combining a diagnostic with a cytotoxic function 
(theranostic gene) by its ability to transport diagnostic and therapeutic radionuclides.  
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1.5 The Sodium Iodide Symporter (NIS) 
1.5.1 Characteristics 
 
The sodium iodide symporter (NIS; SLC5A5) is an intrinsic transmembrane glycoprotein that 
consists of 643 amino acids in humans arranged in 13 putative transmembrane segments 
(Figure 2 left). NIS belongs to the solute carrier family 5 (SLC5) that transports negatively 
charged solutes into the cytoplasm. The symporter actively co-transports two sodium (Na+) 
and one iodide ion (I-) across the basolateral membrane into thyroid follicular cells (Figure 2 
right). The transfer is electrogenic, driven by the electrochemical sodium gradient provided by 
the ouabain-sensitive Na+/K+-ATPase. The efflux of I- into the follicular lumen is not yet fully 
understood, but thought to be in part dependent upon the chloride/iodide transporter pendrin, 
chloride channels, and/or the sodium-monocarboxylate transporter [13]. I- transport across the 
basolateral membrane is the first and crucial step of thyroid hormone synthesis, in which later 
I- is oxidized to iodine (I2) catalyzed by the thyroperoxidase (TPO). This is followed by the 
covalent incorporation of I2 into the backbone of the protein thyroglobulin (TG) in a process 
called iodide organification. The last step, the coupling of iodotyrosine residues, results in the 
thyroid hormones (TH) tri-iodothyronine (T3) and thyroxine (T4). The thyroid hormones are 
stored in the colloid and released into the bloodstream triggered by thyroid-stimulating 
hormone (TSH). In addition, TSH, acting through the cAMP signal transduction pathway, is the 
key regulator of I- transport and NIS expression in the thyroid at transcriptional and post-
transcriptional levels [13, 14]. Physiologically, thyroid hormones are important for the 
maturation, growth and metabolism of various organs, especially for the development of the 
nervous system and the brain. This illustrates the great significance and clinical impact of NIS.  
Figure 2 Schematic illustration of the protein structure of the sodium iodide symporter (NIS) (left) and the role of 
NIS in thyroid hormone synthesis (right) adapted from Spitzweg et al. 2001, Hingorani et al. 2010, and Ravera et 
al. 2017. 
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In addition to the thyroid gland, NIS is also endogenously expressed at lower levels in other 
tissues including the salivary glands, the gastric mucosa, the choroid plexus, the ciliary body 
of the eye, and the mammary glands during lactation. However, the expression of non-thyroidal 
NIS is not TSH-regulated and only the thyroid is equipped with an efficient iodide organification 
system [15, 16]. 
NIS is also able to transport various other anions, such as thiocyanate (SCN-), nitrate (NO3-), 
chlorate (ClO3-), or tetrafluoroborate (TFB [BF4-]) [17, 18]. However, not all of them are 
transported with the same stoichiometry as I- (1:2), the transport of Na+ and ClO4- for example, 
was found to be electroneutral (1:1) [19]. Recently, it was shown that the very low intrinsic 
affinity of NIS for I- increases tenfold, when NIS has bound two Na+ ions. For this reason, 
approximately 79% of NIS molecules have bound two Na+, thereby allowing a sufficient I- 
uptake, despite the submicromolar I- serum concentration [20]. 
 
1.5.2 Theranostic function of NIS 
The variety of potential substrates of NIS has opened the prospect of using specific 
radioisotopes for imaging techniques or therapy modalities, which constitutes the “theranostic” 
(therapy + diagnostic) function of NIS. The commercially available radioisotopes 123I, 131I and 
99mTc can be used for whole body scintigraphy using a gamma camera to visualize thyroid 
cancer and metastases. In addition to scintigraphy, single photon emission computed 
tomography (SPECT) and positron emission tomography (PET) are routinely performed in the 
clinic using radioisotopes such as 125I, 131I, 99mTc, and 188Re (SPECT) or 124I and 18F-TFB (PET), 
that provide a higher resolution and 3D images [20]. After the diagnostic evaluation of a thyroid 
tumor by imaging, an exact personalized dosimetric calculation can be performed for a 
therapeutic application of radionuclides. Based on their β-particle emitting properties, the 
radionuclides 131I, 188Re, and 211At are feasible for therapeutic purposes [15, 20, 21].  
Introduction 
7 
 
Radiation causes ionization or excitation of cellular components, which leads to the breaking 
of chemical bonds and the formation of free radicals, causing damage to proteins, especially 
the induction of double-strand breaks of the DNA. Cells hit by ionizing radiation mostly undergo 
apoptosis [22]. The crossfire effect of the β-particle with a path length of 2.4 mm in tissue as 
is seen with 131I reaches cancer cells neighboring the 131I incorporating cells, thereby causing 
a so-called bystander effect (Figure 3). 131I has been used in the clinic since 1946 with great 
success as first line treatment for differentiated thyroid cancer after thyroidectomy with a well-
known safety profile [13]. The effectivity of this method makes thyroid cancer one of the best 
manageable types of cancer with an overall survival of over 90% [23]. 
The described dual function of NIS allows non-invasive diagnostic imaging of functional NIS 
gene expression before proceeding with a highly effective therapeutic application of 131I for 
thyroid cancer. Excitingly, the transfer of the NIS gene to non-thyroidal tumors opens the 
prospect of radioiodide imaging and therapy of other cancer types besides thyroid cancer. 
Figure 3 Schematic representation of the bystander effect of NIS in a tumor cell based on the crossfire effect of a 
β-emitting particle, adapted from Spitzweg and Morris 2002. 
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1.5.3 NIS Gene Therapy 
 
Figure 4 Concept of theranostic NIS gene therapy adapted from Spitzweg and Morris 2002. 
NIS represents in many ways an ideal reporter and therapy protein. As it is a normal human 
gene and protein, it is non-immunogenic. It shows a high degree of specificity as native 
expression in tissues other than the thyroid is low. The over 70 years of experience with 131I 
therapy has shown a well-characterized safety profile in patients [22]. The potential damage 
to the salivary glands causes mostly minor side effects such as xerostomia or dry mouth, which 
are well manageable especially when compared to the benefit of good tumor growth control. 
Patients can be pre-treated with L-T4 in order to downregulate NIS expression and thereby 
reduce 131I uptake of the normal thyroid to reduce the harm to the thyroid. Overall, the high 
degree of individual, personalized therapy options by using different radionuclides for a broad 
range of imaging modalities and the high efficacy of radioiodide therapy make NIS an 
outstanding theranostic gene for a cytoreductive gene therapy approach (Figure 4). 
Following the cloning of the NIS gene in 1996 [24], initial experiments of ex vivo NIS gene 
transfer [25] and local NIS gene delivery by intratumoral injections were conducted [26]. 
Subsequently, a series of diverse approaches have been evaluated for the systemic in vivo 
gene transfer into non-thyroidal tumors using viruses, nanoparticles or mesenchymal stem 
cells (MSCs) as carriers. 
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The concept of exogenous administration of NIS has been investigated in various in vitro and 
in vivo tumor models including multiple myeloma [27], neuroblastoma [28], anaplastic thyroid 
cancer [29], glioma [30], cancer of the liver [31], the colon [32, 33], the breast [34], the pancreas 
[35-37], and the prostate [26, 38-41]. These very promising proof-of-principle studies have led 
to the use of NIS as imaging and/or therapy gene in phase I/II clinical trials in various non-
thyroidal cancer entities (NCT01503177, NCT01846091, NCT02364713, NCT02700230, 
NCT02919449, NCT02962167, NCT03120624, NCT03171493, NCT03647163), including 
prostate cancer (NCT00788307), and multiple myeloma (NCT00450814, NCT02192775, 
NCT03017820).  
A variety of modified viruses represent the most common shuttle vectors for gene therapy and 
were used in around two thirds of all gene therapy clinical trials conducted in 2017 [11]. This 
also applies to the majority of the preclinical and clinical NIS gene therapy trials underway. 
Early studies by Prof. Dr. Christine Spitzweg and her group using human NIS linked to the 
cytomegalyvirus (CMV) or to the mouse alpha-fetoprotein (AFP) promoter were able to 
demonstrate an efficient tumor-selective NIS gene transfer to prostate cancer or hepatocellular 
carcinoma (HCC), respectively, after local infection [26, 42]. A replication-selective oncolytic 
adenovirus using the same AFP promoter construct for transcriptional targeting of NIS 
expression was developed to increase transduction and therapeutic efficacy by an additional 
oncolytic effect. This approach showed a markedly improved survival as compared to 
virotherapy alone [43]. However, in the case of systemic application, a significant concentration 
of virus was found in the liver. In addition, the induction of immune and inflammatory 
responses, and the elimination of the viral vectors by neutralizing antibodies represent 
common limitations of adenovirus-mediated gene therapy. To help address this issue, Dr. 
Geoffrey Grünwald in the Spitzweg laboratory evaluated the efficacy of adenoviral vectors that 
had been coated with poly(amidoamine) dendrimers (PAMAM). He was able to demonstrate 
significantly reduced hepatic transgene expression levels after systemic injection and an 
enhanced tumor targeting [44]. The use of tumor-specific ligands such as GE11 for the 
epidermal growth factor receptor (EGFR), which is upregulated in a large number of tumors, 
has also been used to improve tumor selectivity and, subsequently, the safety of virus-
mediated gene therapy. Combining an EGFR-targeting with a dendrimer-coated adenovirus 
for NIS gene delivery was found to result in reduced liver toxicity and a strongly enhanced 
therapeutic effect, as seen by significantly reduced tumor growth and improved survival [45]. 
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The use of viral vectors generally include the risk of infecting tissues other than tumors. In 
addition, their genetic loading capacity is limited and they may provoke an unwanted immune 
response. Therefore, synthetic, non-viral vectors that mimic viral behavior have emerged as a 
new research area, in particular as systems that can be formulated in a purposeful way with 
multifunctional domains that address the challenges of improved safety, exact targeting, and 
easy upscaling [46]. 
In collaboration with Prof. Dr. Ernst Wagner and his laboratory at the Department of Pharmacy, 
LMU Munich, Dr. Kathrin Klutz in the Spitzweg laboratory conducted the first studies of 
synthetic polymers for NIS gene therapy using oligoethylenimine (OEI)-grafted 
polypropylenimine dendrimers (G2-HD-OEI) [28]. In subcutaneous (s.c.) syngeneic 
neuroblastoma tumors and HCC xenografts, the G2-HD-OEI-polymers complexed with NIS 
DNA (polyplex) yielded a high tumoral accumulation of polyplexes leading to functional NIS 
expression in the tumor [28, 47]. In the next developmental step novel linear polyethlenimine 
(LPEI) based polymers, shielded by polyethylenglycol (PEG) to reduce toxicity and prolong 
blood circulation time, were combined with an incorporated peptide GE11 as EGFR-specific 
ligand. These agents were shown to improve tumor specific targeting and enhance 
internalization rates [48]. For successful translation of this polymer-based approach to clinical 
trials in humans, the feasibility of the established vectors was tested in advanced tumor 
models, such as disseminated colon cancer metastases [49] and pancreatic ductal 
adenocarcinoma (PDAC) [36]. In order to exploit the potential of polymers to employ a broad 
platform of ligands, in a subsequent study, Dr. Sarah Urnauer investigated the peptide 
sequence CGHKAKGPRK (B6) as a second potential tumor-selective peptide, which was 
originally obtained from a phage display screen for TfR-binding, but for which the cellular 
receptor remains unknown. B6 when used as a targeting ligand for systemic NIS gene delivery 
showed high tumoral levels of NIS protein expression leading to a strong therapeutic effect 
after radioiodide application [50]. In order to further enhance efficacy, as well as to minimize 
response failure due to tumor heterogeneity, a bifunctional polymer was subsequently 
developed that simultaneously targets two potential tumor-expressed receptors (EGFR and 
cMET/HGFR) for NIS gene therapy. The therapeutic efficacy of the dual-targeting concept 
resulted in significantly reduced tumor growth and perfusion, which was associated with 
prolonged animal survival [51]. As a next step towards a future clinical application, additional 
polymers were developed in the laboratory of Prof. Dr. Ernst Wagner designed to further 
improve systemic application of NIS with advanced safety, biocompatibility, and transduction 
efficacy. A novel sequence-defined polymer containing polyethylene glycol (PEG) and cationic 
(oligoethanoamino) amide cores coupled with a cMET-binding peptide (cMBP2) was found to 
allow a well-optimized transfection efficiency resulting in a significant therapeutic response, 
while dramatically reducing toxicity [52]. 
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An additional novel non-viral method for systemic gene transfer currently under study is the 
use of adoptively applied genetically modified mesenchymal stem cells (MSCs) as gene 
delivery vehicles, based on their innate tumor tropism of MSCs and ease of isolation and 
genetic modification. 
 
1.6 Mesenchymal Stem Cells (MSCs) 
1.6.1 Characteristics of MSCs 
MSCs are defined as multipotent progenitor cells that are found in many tissues including the 
bone marrow and that are capable of differentiating into multiple cell types including 
osteocytes, chondrocytes, smooth muscle cells, stromal cells, and fibroblasts [53, 54]. They 
are characterized by a fibroblast-like morphology, a phenotypically specific cell surface marker 
profile [55, 56], adherence to cell culture plastic, and a high in vitro expansion potential [55, 
57, 58]. In vivo, MSCs have the unique property of active migration from a tissue niche to the 
peripheral circulation and eventually to sites of tissue damage or ischemia [54]. Many different 
groups have demonstrated the systemic delivery of MSCs to sites of tissue damage, such as 
the myocardium after myocardial infarction [59, 60], brain injuries after cerebral ischemia [61] 
or the lungs in a model of pulmonary fibrosis [62]. In addition, MSCs have low immunogenicity 
and potentially avoid immune rejection. 
 
1.6.2 MSCs as Gene Transfer Vehicles 
MSCs possess the innate ability to traffic to sites of inflammation and tissue injuries, including 
those present in cancer [63], as tumor stroma formation is thought to resemble a chronic wound 
[64, 65]. The homing of MSCs depends mainly on the combined effects of various inflammatory 
cytokines, chemokines, and growth factors secreted by the tumor and the tumor 
microenvironment [66-68]. The active recruitment of adoptively applied MSCs to various types 
of cancer, such as breast cancer [69], glioma [30, 70], colon cancer metastases [32], and 
hepatocellular carcinoma (HCC) [71, 72] has been demonstrated. These and other features 
make MSCs attractive candidates as therapy vehicles for the targeted delivery of therapeutic 
agents into the microenvironments of growing tumors [67]. 
One approach that has shown efficacy in this regard was the engineering of MSCs to 
constitutively secrete immunomodulatory anticancer proteins such as IFN-β, IL-2, or IL-12 [73, 
74]. A second general approach that has been subsequently shown to have strong anti-tumor 
effects was to modify MSCs to produce the tumor necrosis factor-related apoptosis inducing 
ligand (TRAIL) in order to directly induce apoptosis [75]. 
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Another strategy consists of loading MSCs with therapeutic drugs such as doxorubicin [69] or 
paclitaxel [76] for the direct transport of these agents to the tumor stroma. MSCs have also 
been used for the delivery of oncolytic viruses such as a conditionally replicative adenovirus 
or measles virus [77] (reviewed recently in [78, 79]) to growing tumors. A different general 
approach has used engineered versions of MSCs to deliver a therapeutic suicide gene, such 
as the herpes simplex virus type 1 thymidine kinase (HSV-TK), to selectively target tumors of 
the breast, pancreas, brain, and liver [80-83]. The subsequent therapeutic administration of 
ganciclovir, which is exclusively phosphorylated by HSV-TK, results in the formation of toxic 
metabolites and thereby reduced primary tumor growth and the incidence of metastases in 
vivo [84]. The safety and tolerability of this approach in patients with advanced gastrointestinal 
adenocarcinoma has been subsequently confirmed in a phase I/II clinical trial [85]. 
The sodium iodide symporter (NIS) described above, represents an important and promising 
theranostic gene for future clinical development of MSC-mediated gene therapy. 
 
1.6.3 MSC-mediated NIS Gene Therapy 
Due to their excellent tumor-homing properties, MSCs engineered to express NIS have been 
shown to efficiently migrate to solid tumors as evidenced by the tracking of NIS signal. In 
addition, NIS allows the characterization of whole body biodistribution of the engineered cells 
prior to NIS-mediated radioiodide therapy. Using this approach, successful MSC-mediated 
transfer of the NIS-transgene has been seen in various cancer entities, such as HCC [31, 72], 
glioma [30], breast cancer [34], prostate cancer [26, 40, 41], colon cancer metastases [32], 
multiple myeloma [27], and pancreatic ductal adenocarcinoma [35, 37]. In each of these cases, 
the subsequent therapeutic administration of 131I led to a significantly decreased tumor growth 
with a prolonged survival of animals in vivo [31, 82, 86, 87]. 
The first proof-of-principle experiments with NIS-MSC were performed in Prof. Spitzweg’s 
laboratory in close collaboration with Prof. Dr. Peter Nelson, Medizinische Klinik IV, LMU 
Munich, using MSCs stably expressing NIS under control of the constitutively active CMV 
promoter (CMV-NIS-MSCs). The experiments confirmed a tumor-selective MSC-mediated NIS 
gene transfer to s.c. HCC xenograft tumors [86]. The administration of 131I resulted in a 
significant delay in tumor growth as compared to controls. The selective expression of 
transgenes such as NIS within the tumor environment was thought to be crucial to limiting 
potential off target side effects. A degree of selective control of transgene expression can be 
achieved by the use of gene promotors linked to signal or differentiation pathways that occur 
mostly or sometimes only within the tumor microenvironment. 
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In a more refined approach, more tumor stroma specific gene promoters were evaluated: Dr. 
Kerstin Knoop successfully investigated MSCs expressing NIS under the control of the tumor 
stroma-inflammatory RANTES/CCL5 promoter [72] and Dr. Andrea Müller developed MSCs 
driven by an hypoxia responsive synthetic promoter activated by tumor hypoxia [31]. In 
addition, by building on the role of transforming growth factor B1 (TGFB1) and the SMAD 
downstream target proteins in the context of tumor and tumor stroma biology, Dr. Christina 
Schug developed MSCs which express a synthetic SMAD-responsive promoter [87]. Most 
recently, Dr. Kathrin Schmohl used a vascular endothelial growth factor (VEGF)-NIS construct 
to target tumor angiogenesis [88]. 
In these settings, the biodistribution of the genetically engineered MSCs was analyzed by 123I-
scintigrahy or 124I- and 18F-TFB PET-imaging using NIS as reporter gene in s.c. and orthotopic 
HCC xenografts and colon cancer metastases in vivo tumor models. The efficient recruitment 
of MSCs after systemic application and with administration of 131I, a significant reduction of 
tumor growth and prolonged survival of the animals was seen, further demonstrating the 
potential of NIS as a theranostic gene. 
 
1.6.4 How to Improve MSC Efficacy 
Effective homing of MSCs to the tumor stroma is crucial for a successful MSC-mediated 
therapeutic approach; therefore, an improvement in active engraftment of MSCs at the tumor 
site is of great interest. Priming MSCs in culture with chemokines, such as tumor necrosis 
factor (TNF)-α [89], or keeping them under hypoxic conditions [90], can result in an increased 
migratory behavior of MSCs in vitro and in vivo. The upregulation of chemokine receptors, 
such as CXCR4, is also able to boost tumor homing, as the CXCR4-SDF-1 axis was found to 
be a key regulator of MSC recruitment [91] (reviewed in [66]). 
Another promising approach is to combine existing anticancer strategies such as 
chemotherapy or radiotherapy with NIS gene therapy. External beam radiation therapy (EBRT) 
has been shown to upregulate the chemokines and cytokines needed for MSC recruitment [92, 
93]. Dr. Christina Schug in the group of Prof. Spitzweg recently demonstrated a significantly 
enhanced selective migration of MSCs after pre-treatment of tumors with EBRT in HCC 
xenograft tumors [94]. Combining the concept of EBRT with TGFB1-mediated NIS induction 
(SMAD-NIS-MSCs) yielded a dramatically improved therapeutic efficacy with tumor remission 
in a subset of animals [95]. 
Similarly, regional hyperthermia, another established antitumoral therapy modality, has been 
proposed to upregulate the inflammatory machinery of the body as well as to condition the 
tumor for an enhanced therapy response. 
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1.7 Hyperthermia 
Hyperthermia is characterized by the elevation of body or tissue temperature in response to 
exogenous heat stimulation, reaching temperatures from 39 °C to 42.5 °C in a clinical setting. 
In contrast to fever, the temperature rise occurs without the presence of a pyrogenic agent [96, 
97]. Hyperthermia is under intense investigation in the clinic as an adjuvant in multimodal 
cancer treatment approaches, especially for superficial tumors such as sarcoma, melanoma, 
breast, or colon cancer [98], as heat shows great chemo- and radiosensitizing qualities. A sub-
lethal damage to a cancer cell caused by chemo- or radiotherapy can be enhanced to a lethal 
dose by the administration of heat. Non-invasive monitoring and precise adjustment of heat is 
essential. As of late, this is achieved in the clinic by using hybrid magnetic resonance-guided 
high-intensity focused ultrasound that allows simultaneous real-time temperature mapping of 
the heated region and energy deposition [99]. 
Mild hyperthermia, at temperatures in the range of 39 to 44 °C, is able to disturb the de novo 
synthesis of DNA by denaturation of synthetases and polymerases which leads to an arrest of 
the cell cycle. It can also induce apoptosis or necrosis and interfere with a number of DNA 
repair mechanisms [100]. In addition, changes of the fluidity and stability of cell membranes, 
resulting in modifications of the cytoskeleton are reported in response to hyperthermia. 
Recently, hyperthermia has gained interest in the context of oncological immunotherapy, 
especially concerning the therapy of metastases, as it can activate immune cells, initiate the 
release of exosomes and HSPs that present tumor antigens, and enhance surface molecule 
expression on heated tumor cells. Thus, the immunogenicity of tumor cells is increased. Lately, 
a phenomenon called the abscopal effect, which was first described for local radiotherapy, was 
also detected for hyperthermia. It describes the finding that local tumor treatment at one site is 
able to affect the growth of distant tumors and metastases. This effect is presumably mediated 
by activation of the immune system [101-104]. Furthermore, regional hyperthermia has been 
proposed to activate cells of the innate immune system [105]. It has been reported that, for 
example, natural killer cells or neutrophils show enhanced recruitment in response to heat 
application [106]. In addition, the enhanced trafficking of lymphocytes from draining tissues to 
secondary lymphatics triggered by heat treatment was shown to be potentially provoked by an 
increased expression of chemokines linked to lymphoid migration [101, 107].  
Though the exact underlying molecular mechanisms of MSC migration are not yet fully 
understood, they are thought to resemble the processes underlying the recruitment of 
leukocytes to inflammatory tissues [66] which is mediated by high local concentrations of 
chemokines. This opens the exciting prospect of employing hyperthermia-induced 
amplification of chemokine secretion to augment MSC migration.  
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2. Aims of the Thesis 
The previous work of Prof. Dr. Christine Spitzweg and her laboratory in collaboration with Prof. 
Dr. Peter Nelson and Prof. Ernst Wagner clearly demonstrated the enormous potential of 
genetically engineered mesenchymal stem cells (MSCs) for the tumor-selective delivery of the 
NIS gene. NIS as a well-characterized theranostic gene allows for the detailed non-invasive in 
vivo tracking of MSCs by 123I-scintigraphy and 124I-PET imaging, as well as effective therapeutic 
application of radionuclides (131I, 188Re). As a logical consequence of the successful proof-of-
principle studies, and as a next step towards clinical application, the primary goal of this thesis 
was evaluation of the potential enhancement of the effectiveness, and tumor selectivity, of 
MSC-mediated NIS gene therapy through the combination with regional hyperthermia 
protocols. 
The first aim of this thesis was the investigation of the stimulatory effect of regional 
hyperthermia with regards to the selective recruitment of MSCs to the tumor stroma in vitro 
and in vivo through heat-induced stimulation of cytokine secretion.  
The second aim was the establishment of MSCs stably expressing NIS under the control of a 
heat-inducible HSP70B promoter. The application of heat-inducible promoters could in theory 
allow a spatial and temporal control of high level transgene expression by regional 
hyperthermia applied after MSC administration, thereby inducing strong promoter activation 
independent of their differentiation pathway (as compared to the previous use of TGFB1 or 
RANTES promoter).  
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3. MSC-mediated NIS Gene Therapy 
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3.1 Abstract 
The tropism of mesenchymal stem cells (MSCs) for growing tumor forms the basis for their 
use as gene delivery vehicles for the tumor-specific transport of therapeutic agents, such as 
the sodium iodide symporter (NIS). The NIS gene encodes a theranostic protein that allows 
non-invasive monitoring of the in vivo biodistribution of functional NIS expression by 
radioiodine imaging as well as the therapeutic application of 131I. Regional hyperthermia is 
currently used as an adjuvant for various tumor therapies and is reported to enhance the 
secretion of immunomodulatory chemokines, cytokines and growth factors, well-known 
attractants of MSCs.  
Methods: Following hyperthermia (41 °C for 1h) of experimental human hepatocellular 
carcinoma cells (HuH7) the chemokine secretion profile was analyzed by RT-PCR and 
chemotaxis of MSCs was tested in a 3D live cell tracking migration assay. An in vivo 
subcutaneous HuH7 mouse xenograft tumor model was used, where a single systemic 
injection of CMV-NIS-MSCs was applied 6h, 24h, 48h after or 24h, 48h before hyperthermia 
treatment and tumoral 123I accumulation was assessed by 123I-scintigraphy. The optimal 
imaging regime was then used for a 131I therapy study 
Results: Chemokine mRNA analysis indicated a substantial increase in expression levels after 
heat exposure. Enhanced chemotaxis of MSCs was found in relation to a gradient of 
supernatants from untreated to heat-treated cells. The optimal in vivo regime showed 
significantly increased 123I-uptake in tumors of heat-treated animals (41 °C) when 
thermostimulated 24h after CMV-NIS-MSC injection compared to control animals (37 °C). Ex 
vivo affirmed by NIS-specific immunohistochemistry and RT-PCR, thereby confirming tumor-
selective, temperature-dependent MSC migration. Therapeutic efficacy was demonstrated 
following CMV-NIS-MSC-mediated 131I therapy combined with regional hyperthermia that 
resulted in stimulation of tumor growth reduction associated with prolongation of survival in the 
regional heat-treated animals as compared to normothermic mice or to the saline control group. 
Conclusion: In the present report, we described the enhanced recruitment of adoptively 
applied MSCs engineered to express the theranostic NIS gene to tumors in response to 
regional hyperthermia. 
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3.2 Introduction 
Thermal therapy (hyperthermia) is an emerging therapeutic modality for the treatment of 
cancer that makes use of the diverse biological effects that occur following regionally induced 
heating. Hyperthermia, in contrast to fever, is defined as addition of excess heat resulting in a 
rise of tissue or core temperature without a regulated change in the hypothalamic set point, 
and in absence of pyrogenic agents [96]. While the intrinsic biologic effects of elevated 
temperature in cancer tissues is still not well understood, it has been well-demonstrated that 
increasing the temperature of the tumor (39 °C to 42.5 °C) acts as an adjuvant in multimodal 
cancer treatment schemes in clinical practice [96, 108]. Hyperthermia is able to induce 
irreversible cellular DNA damage, to interfere in the DNA repair response cascades, to alter 
the fluidity and stability of cell membranes, and concomitantly modify the cytoskeleton in 
treated cells. These physiological changes effectively sensitize tumor cells to chemo- or 
radiotherapy and can thus enhance the beneficial effects of therapeutic strategies that target 
DNA stability [109]. In addition, studies are currently underway using thermally labile liposomes 
to enhance the targeting of chemotherapy agents during regional hyperthermia [110]. 
Regional hyperthermia has also been proposed to induce tumor immunogenicity and can result 
in enhanced systemic tumor control by stimulating immune control of both primary tumor and 
metastases [105], especially cells of the innate immune system can be activated by heat. The 
best studied phenomenon in this regard involves the enhanced trafficking of lymphocytes from 
draining tissues to secondary lymphatics in response to hyperthermia, primarily by the 
enhanced expression of chemokines, integrins and the chemokine receptors linked to 
lymphoid migration (CCL21, ICAM and CCR7) [recently summarized in [101, 107]]. 
Mesenchymal stem cells (MSCs) also show a pronounced capacity for recruitment to growing 
tumors, the exact molecular mechanisms at work are not fully understood, but are thought to 
parallel the processes underlying the recruitment of leukocytes from the peripheral circulation 
to inflamed tissues [66]. 
MSCs are defined as multipotent progenitor cells that are capable of differentiating into multiple 
cell types including osteocytes, chondrocytes, smooth muscle cells, stromal cells, and 
fibroblasts [53]. In vivo, MSCs have the unique property of migration from the bone marrow or 
other tissue niches to the peripheral circulation followed by their active recruitment to sites of 
tissue damage and ischemia, as generally present in solid tumors [54]. The recruitment of 
adoptively applied MSCs to various cancer types, such as breast cancer [69], glioma [30, 70], 
multiple myeloma [111], ovarian cancer [63], colon cancer metastases [32],  hepatocellular 
carcinoma (HCC) [71, 86], as well as pancreatic cancer [35-37] has been demonstrated by 
various groups including ours. 
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This general feature has made engineered versions of MSCs attractive candidates for the use 
as shuttle vectors to efficiently deliver a therapeutic gene or agent deep into 
microenvironments of growing tumors [67]. The homing of MSCs is thought to depend on the 
combined effects of various inflammatory cytokines, chemokines, and growth factors secreted 
within the tumor microenvironment [112]. Hyperthermia has been shown to enhance the 
release of thpse inflammatory chemokines and cytokines shown to attract MSCs [105, 107, 
113]. We hypothesized that mild regional hyperthermia could act as a means of enhancing the 
selective recruitment of MSC to the tumor stroma and thus open the exciting prospect of 
enhancing tumor selectivity as well as the therapeutic efficacy of MSC-mediated cancer gene 
therapy. 
In the present report, we characterized the stimulatory effect of regional hyperthermia on 
recruitment of adoptively applied MSCs, engineered to express the theranostic sodium iodide 
symporter (NIS) gene, to experimental hepatocellular tumors. When used as a reporter gene, 
NIS allows non-invasive monitoring of the in vivo biodistribution, level and duration of functional 
NIS expression by 123I-scintigraphy, 124I-PET, or 99mTcO4-SPECT imaging [31, 32, 37, 72, 86, 
87, 94, 95, 114, 115]. The biology of NIS as a therapy gene has been widely applied in patients 
for over 70 years allowing a highly effective therapeutic application of 131I, or alternative 
radionuclides such as 211At or 188Re [13, 16].  
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3.3 Material and Methods 
Cell culture 
SV40 large T antigen-immortalized human bone marrow-derived MSCs were stably 
transfected with NIS driven by the CMV promoter (CMV-NIS-MSCs) and cells were cultured 
as described previously [86]. For heat-treatment cell culture dishes were sealed with parafilm 
and submerged in a circulating water bath for 30 to 120 minutes at 40 to 42 °C followed by a 
recovery time in an incubator at 37 °C (5% CO2, 95% humidity) for 0-7 days. 
 
125I uptake assay and cell viability assay 
Functional NIS expression was determined in vitro using a 125I uptake assay and cell viability 
was determined using a commercially available thiazolyl blue tetrazolium blue (MTT) reagent, 
as described previously [116]. Results were normalized to cell survival and expressed as 
counts per minute (cpm) / A620.  
 
HuH7 supernatants 
1 x 106 HuH7 cells were seeded in a 100 mm3 cell culture dish and 12 hours before 
thermostimulation full growth medium was replaced by serum-free DMEM. Supernatants from 
heat-treated and non-treated cells were collected 0 to 48 hours after heat treatment and 
immediately stored at -80 °C. 
 
Quantitative real-time PCR and ELISA 
HuH7 RNA und supernatants for ELISA were isolated 0 - 48 hours after hyperthermia of heat-
treated and control cells as described previously [95]. Quantitative real-time (RT)-PCR was 
run in a Mastercycler ep gradient S PCR cycler (Eppendorf, Hamburg, Germany) or a 
Lightcycler 96 System (Roche, Basel, Switzerland) using the primers listed in Supplementary 
Table 1. 
 
3D migration assay 
Chemotaxis of CMV-NIS-MSCs, seeded in collagen I (0.3 x 106 cells/ml), in relation to a 
gradient of unheated and heat-treated HuH7 supernatants was tested in a live cell tracking 
migration assay using the µ-slide Chemotaxis3D system (ibidi, Planegg, Germany) and 
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monitored by time-lapse microscopy (Leica Microsystems, Wetzlar, Germany) for 24 hours as 
described previously [94].  
 
In vivo regional hyperthermia 
Establishment of subcutaneous HuH7 xenograft mouse model in female CD1 nu/nu mice 
(Charles River Laboratories, Wilmington, Massachusetts, USA) was performed as described 
previously [86]. All animal experiments were approved by the regional governmental 
commission for animals (Regierung von Oberbayern, Munich, Germany). For regional 
hyperthermic treatment, mice were anesthetized by inhalation of isoflurane/oxygen anesthesia 
and placed on top of a water bath at 41 °C or, as control, at 37 °C for 1 hour. The water bath 
was covered with a plastic plate specifically designed to allow only the tumor bearing leg to be 
submerged into the water, through small holes in the plastic cover. Body temperature was 
monitored using a rectal thermometer (Homeothermic Blanket Systems with Flexible Probe; 
Harvard Apparatus, Massachusetts, USA). 
 
123I-scintigraphy after NIS gene transfer 
When the tumors reached a volume of 500-800 mm3, a single systemic injection of 0.5 x 106 
CMV-NIS-MSCs into the tail vein was applied to HuH7 tumor-bearing mice and hyperthermia 
was locally applied either 48 hours, 24 hours or, 6 hours before, or 24 hours or 48 hours after 
MSC injection. 72 hours after MSC administration, mice received 18.5 MBq of 123I (GE 
Healthcare Buchler GmBH & Co. KG, Braunschweig, Germany) intraperitoneally (i.p.) and 
iodide biodistribution was measured by serial scanning on a gamma camera (e.cam, Siemens, 
Munich, Germany) using a low-energy, high resolution collimator. As control of NIS-specific 
iodide accumulation, perchlorate (Merck KGaA, Darmstadt, Germany) was injected 30 min 
prior to 123I injection. Regions of interest (ROIs) were analyzed by HERMES GOLD (Hermes 
Medical Solutions, Stockholm, Sweden) software and tumoral iodide accumulation was 
expressed as % of the injected dose (ID) per gram tumor (% ID/g). Dosimetric calculations 
were performed using the Medical Internal Radiation Dose (MIRD) technique with a RADAR 
dose factor (www.doseinfo-radar.com). 
 
Ex vivo analysis 
Immunohistochemical staining of paraffin-embedded tumor sections and control organs was 
performed using a NIS-specific antibody (Merck Millipore; dilution 1:500) as described 
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previously [117]. Tumor samples taken 8 hours, 24 hours, and 48 hours after heat treatment 
(including 8 hours 123I-scintigraphy) were analyzed by RT-PCR. ΔΔ-Ct values were normalized 
to the internal control (the average of β-actin, UBC and r18s). 
 
131I-therapy study 
When tumors had reached a size of 5mm in diameter, the drinking water was supplemented 
with 5 mg/ml L-T4 (Sigma Aldrich) and the mice received a low iodine diet (ssniff Spezialdiäten 
GmbH, Soest, Germany) to reduce thyroidal iodide uptake and thereby potentially enhance 
tumoral iodide accumualtion. At a tumor volume of around 100 mm3, the mice received a single 
systemic injection of CMV-NIS-MSCs via the tail vein, followed by hyperthermic treatment (41 
°C or 37 °C for 1 hour) 24 hours later. 2 days after hyperthermia 55.5 MBq 131I was applied 
intraperitoneally (CMV-NIS-MSCs + 41 °C + 131I, n = 8; CMV-NIS-MSCs + 37 °C + 131I, n = 7). 
As control group, MSCs and 131I was replaced by saline and mice were treated with 37 °C 
(NaCl + 37 °C + NaCl, n = 5). Mice were sacrificed based on tumor growth (tumor volume 
exceeded 1500 mm3) and animal care protocols. 
 
Statistical analysis 
All in vitro experiments were performed at least three times and values are expressed as mean 
± SEM. Statistical significance was tested by two-tailed Student’s t-test or by ANOVA with post-
hoc Tukey (honestly significant difference) test for multiple comparisons. Survival was plotted 
by Kaplan-Meier survival plots and analyzed by log rank test. p-values < 0.05 were considered 
significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
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3.4 Results 
 
Figure 5 Hyperthermia effects in vitro. The effect of hyperthermia on HuH7 cells in vitro was analyzed by MTT 
assay 24 hours after heat treatment. Red line represents the cell viability of the 37 °C controls (A; dotted graph). 
Following hyperthermia at 41 °C for 60 minutes, long-term cell viability was evaluated (B). In vitro iodine uptake of 
CMV-NIS-MSCs was determined by a 125I uptake assay (C). In addition, the effects of hyperthermia on the iodine 
accumulation by CMV-NIS-MSCs (D) and their viability (E) was evaluated. 
 
Effects of hyperthermia on cell survival 
Hyperthermic treatment led to acute cell killing only when the heat treatment was applied for 
an extended period of time (120 minutes) or at higher temperatures (42 °C) (Figure 5 A). In a 
long-term cell survival evaluation, following moderate hyperthermia (60 minutes at 41 °C), 
growth of heat-treated HuH7 cells was significantly reduced as compared to controls as seen 
5 and 7 days after heat exposure (Figure 5 B). 
 
Functional NIS expression in vitro 
CMV-NIS-MSCs showed high functional NIS expression (28.114 ± 1516 cpm / A620) in vitro 
as seen in a 125I uptake assay (Figure 5 C), which was sensitive to the NIS-specific inhibitor 
perchlorate (378 ± 60 cpm / A620). Thermostimulation caused no significant difference in 125I 
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accumulation between heated (41 °C) and non-heated cells (37 °C) (Figure 5 D). In addition, 
cell viability, demonstrated no significant alteration in response to mild heat treatment (Figure 
5 E). 
 
Figure 6 Chemokine and cytokine gene expression profile of HuH7 in vitro. RT-PCR analysis of mRNA 
extracted from heat-treated HuH7 cells 0 to 48 hours after hyperthermia compared to non-heated HuH7 using 
primers listed in Supplementary table 1.  
 
Chemokine secretion profile of HCC tumor cells 
mRNA analysis indicated a substantial increase in the expression of growth factors and 
chemokines after heat exposure of HuH7 cells as compared to controls (37 °C) (Figure 6). 
While the chemokine CXCL8, platelet-derived growth factor-β (PDGF-β), vascular endothelial 
growth factor (VEGF), tumor necrosis factor-α (TNF-α), and thrombospondin-1 (TSP-1) levels 
were found to be increased immediately (0-4 hours) following hyperthermia, the chemokine 
CCL15, placental growth factor (PGF), basic fibroblast growth factor (FGF-2), and insulin-like 
growth factor-1 (IGF-1) were increased later (12-24 hours). 48 hours after thermostimulation 
the enhanced expression of all factors tested had returned to untreated control levels. 
Transforming growth factor-β (TGF-β), interleukin-1-beta (IL-1β) and hypoxia-inducible factor-
1-α (HIF-1α), in contrast, were not found to be influenced by thermostimulation, while CXCL12 
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mRNA levels were significantly reduced. No mRNA for hepatocyte growth factor (HGF), 
epidermal growth factor (EGF), CCL2, CCL5 and interleukin 6 (IL-6) was detected (data not 
shown). 
ELISA then confirmed effects seen on the mRNA level on protein level in supernatants of HuH7 
cells, affirming the heat-induced secretion (Figure 7).  
 
 
Figure 7 Protein expression analysis of HuH7 in vitro. Protein levels in culture supernatants derived from heat-
treated HuH7 cells 0-48 hours after hyperthermia were analyzed by ELISA. 
 
MSC-migration 
CMV-NIS-MSCs showed no directed chemotaxis when subjected to supernatants derived from 
untreated HuH7 cells in both chambers (Figure 8 A). However, MSCs under the influence of 
a gradient between supernatants derived from untreated and heat-treated HuH7 cells showed 
directed chemotaxis to supernatants collected 24 hours after thermostimulation (Figure 8 D). 
This effect was even stronger with supernatants collected 48 hours after hyperthermia (Figure 
8 E), whereas only random chemokinesis was seen with supernatants which were collected at 
earlier time points, i.e. 0 hours (Figure 8 B) and 12 hours (Figure 8 C) after heat treatment. 
Quantification of chemotactic parameters revealed a strong increase in yFMI (Figure 8 F) and 
mean directness (Figure 8 I), a slightly increased velocity (Figure 8 G), and a significant rise 
in the mean CoM (red dots) (Figure 8 H) of MSCs towards supernatants from heat-treated 
HuH7 cells, demonstrating enhanced MSC migration. 
MSC-mediated NIS Gene Therapy 
26 
 
 
 
Figure 8 CMV-NIS-MSCs migration assay. MSCs subjected to supernatants derived from untreated HuH7 cells 
in both chambers (A). Cells under the influence of a gradient between supernatants from untreated (top chamber) 
and thermo-stimulated HuH7 cells derived 0 to 48 h after hyperthermia (bottom chamber)  (B-E). Quantification of 
chemotaxis parameters as mean forward migration index (yFMI) (F), velocity (G), the mean center of mass (yCoM; 
red dots) (H), and mean directness (I) of MSCs. 
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123I-scintigraphy 
Quantitative analysis of tumoral radioiodine accumulation after CMV-NIS-MSC application 
(Figure 9 A) revealed significantly increased uptake of 123I in heat-treated as compared to non-
heated tumors (tumoral iodine accumulation 1 hour post 123I injection of 37 °C-controls: 5.4 ± 
0.5% ID/g; n = 6), with the strongest effect found in group D (8.9 ± 1.1% ID/g; n = 6), where 
the MSCs were injected 24 hours prior to the thermostimulation, followed by group E (8.0 ± 
1.5% ID/g; n = 6) and group C (6.5 ± 2.0% ID/g; n = 7), where MSCs were administrated 48 
hours before, or 6 hours after, hyperthermic treatment. In contrast, when heat was applied 24 
hours prior to MSC injection, only a slight rise of tumoral iodine accumulation was seen in 
group B (6.0 ± 0.7% ID/g; n = 6) as compared to controls, and essentially control levels were 
seen in group A (5.9 ± 1.4 %ID/g; n = 6), where regional hyperthermia was administered 48 
hours before the MSCs. The NIS-specific iodide uptake could be blocked by administration of 
perchlorate (Figure 9 B). 
 
Ex vivo analysis 
Analysis of ex vivo steady state mRNA levels for the NIS gene demonstrated significantly 
increased NIS mRNA expression in tumors heated to 41 °C, as compared to controls at 37 °C 
(Figure 9 C). Strong NIS-specific immunoreactivity (red) was visible in the tumor stroma of 
heat-treated tumors whereas controls exhibited weaker signals. No immunoreactivity was 
detected in non-target organs (Figure 9 D). The ex vivo chemokine and cytokine mRNA 
expression profile (Figure 10) showed a time and temperature dependent mRNA expression 
that largely paralleled those seen in the in vitro study (Figure 6). 
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Figure 9 123I-scintigraphy following CMV-NIS-MSC administration. S.c. HuH7 tumor bearing mice were injected 
with CMV-NIS-MSCs and subjected to hyperthermic treatment (1 hour at 41 °C or 37 °C, as controls) at different 
time points (A). One representative image for the best performing hyperthermia treatment group and the control 
group (B). mRNA isolated from frozen tumor sections was analyzed for NIS by RT-PCR (C). NIS-specific 
immunohistochemistry (red) was performed of tumors of 37 °C-control animals and heat-treated tumors of mice 
(group D) and control organs (D). 
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Figure 10 Chemokine and cytokine secretion profile of HuH7 in vivo. mRNA was isolated from frozen tumor 
sections from heat-treated tumors 8 hours, 24 hours and 48 hours later and expression levels of different 
chemokines and cytokines were evaluated by RT-PCR. 
 
In vivo radioiodide therapy study 
Combination treatment with tumoral hyperthermia at 41 °C resulted in a stimulation of tumor 
growth inhibition as compared to 37 °C-controls and to the saline only control group (Figure 
11 A), with a partial tumor remission seen in one mouse. Hyperthermia co-treatment also 
resulted in a prolonged survival (Figure 11 B) (CMV-NIS-MSCs + 41 °C + 131I) as compared 
to the control groups (CMV-NIS-MSCs + 37 °C + 131I and saline only). On day 26 after therapy 
start, all animals of the saline control had to be sacrificed due to tumor volume reaching the 
allowed limit of 1500 mm3, whereas 85.7% of MSC + 131I therapy groups were still alive, 
demonstrating a significantly prolonged overall survival. All mice from the 37 °C controls 
reached endpoint criteria by day 32, at this time point 50% of the hyperthermia group was still 
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vital. The survival of the hyperthermic therapy group was plotted until day 140 and the 
surveillance of two mice was still ongoing at the time of this report. 4 out of 8 heat-treated mice 
showed a similar survival as the normothermic therapy group (around 30 days), whereas 2/8 
lived more than 1 week, and 2/8 even 100 days longer than the controls with a partial remission 
seen in one mouse. 
 
Figure 11 In vivo 131I therapy study. In a s.c. Huh7 xenograft mouse model, the best treatment scheme 
identified in the imaging study was adapted for a therapy study using 131I. Tumor growth (A) and survival (B) were 
monitored for the treatment with CMV-NIS-MSCs, regional hyperthermia, and 131I (red line), compared to the 
normothermic control group (blue line) and the saline only group (grey line).  
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3.5 Discussion 
The response of cancer cells to hyperthermia is of great clinical interest. Its use as an adjuvant 
in multimodal treatment approaches enhances therapeutic effectiveness without increasing 
general toxicity. The benefit of hyperthermia in combination with radio-, chemo-, or radio-
chemotherapy has been well-established in various randomized clinical trials [reviewed in 
[118]]. Hyperthermia is able to induce changes within the tumor microenvironment thought to 
help to trigger an anti-tumor immune response [100, 119]. In addition, hyperthermia is capable 
of increasing the amount of neutrophils, natural killer cells, and lymphocytes in the tumor 
microenvironment [107]. Leukocyte trafficking is a highly regulated process that may be 
influenced by hyperthermia at multiple stages. Hyperthermia can augment lymphocyte 
diapedesis across the endothelial layer, improve their adhesive properties to the endothelium, 
and thereby facilitate their infiltration [106]. 
The well-characterized innate ability of MSCs to traffic to solid tumors [63] is thought to derive 
from the observation that tumor stroma formation resembles a chronic, non-healing wound and 
MSC are recruited to “help repair” the damaged tissue [64, 65]. This general process has been 
adapted by many groups, including our own, as a "Trojan Horse"-like tumor therapy approach 
by using engineered versions of MSCs as vehicles for the delivery of agents deep into the 
tumor environment [63, 67, 120]. This approach has now advanced to clinical trials [[85], 
NCT02530047, NCT03298763].  
In the present study, we characterized the effects of regional hyperthermia on the direct 
recruitment of MSCs, and specifically, on events that occur within hours or days following 
treatment. We could show that in vitro, hyperthermia (41 °C for 1 hour) led to enhanced 
transient production of cytokines and chemokine linked to MSC migration. Cells respond 
metabolically when subjected to a heat challenge. They upregulate heat shock proteins (HSPs) 
and other cell protective proteins, while reducing the steady state levels of genes not involved 
in the heat response [98]. Subsequent mRNA analysis of heat-treated tumor sections ex vivo 
presented a similar cytokine secretion profile as seen in vitro, thereby confirming the 
upregulation of immunomodulatory factors potentially enhancing MSC migration ex vivo. 
These effects were further validated in a 3D migration model that showed enhanced migration 
towards conditioned media taken from heat-treated HuH7 cells, thereby demonstrating for the 
first time the potential of hyperthermia to attract MSCs to heat-treated tumor cells in vitro. 
In a further step towards in vivo application, we investigated the effects of the heat-treatment 
protocol (41 °C for 1 hour) on the cell viability in vitro and observed only a significant reduction 
of cell viability of the cancer (HuH7) cells and not on the MSCs. This confirms the previous 
observation that normal tissues are not damaged during hyperthermia, while tumors, in 
contrast, are more sensitive to hyperthermia [108].  
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The enhanced recruitment effects seen the in vitro experiments were further validated in vivo. 
A promising candidate therapy gene for the next generation of clinical applications of MSC-
mediated cancer gene therapy is the NIS transgene. NIS as a well-characterized theranostic 
gene allows detailed non-invasive in vivo tracking of MSCs by 123I-scintigraphy or 124I-PET 
imaging, as well as the highly effective therapeutic application of radionuclides (131I, 188Re) [13, 
17]. We and others have demonstrated MSC-mediated transfer of therapeutic transgenes to 
diverse cancer entities, including; hepatocellular carcinoma [31, 72], glioma [30], breast cancer 
[34], prostate cancer [26, 40, 41], colon cancer metastases [32], multiple myeloma [27], and 
pancreatic ductal adenocarcinoma [35, 37]. In our studies using the NIS theranostic gene, we 
have found that MSC injections followed by the therapeutic administration of 131I demonstrated 
a significantly reduced tumor growth with a prolonged survival of animals [31, 82, 86, 94]. 
In the present study, a single systemic injection of CMV-NIS-MSCs combined with 
thermostimulation at 41 °C showed that hyperthermia can enhance the selective MSC 
migration towards the tumor stroma in a s.c. HCC (HuH7) xenograft mouse model. Testing the 
application of heat at different time points before and after MSC injection, we observed the 
highest tumoral iodine uptake when injecting MSCs 24 hours prior to hyperthermia (group D). 
After intravenous injection, MSCs are initially trapped in the microcapillaries of the lungs [121] 
and start to migrate from the lungs to other organs, such as the liver, spleen, or kidneys  or, if 
present, to a tumor only after 24 hours [122]. This effect helps explain our observation of the 
highest recruitment seen when applying heat 24 hours post MSC injection, which allowed 
optimized timing of the transiently enhanced tumoral chemokine and cytokine secretion 
following hyperthermia and the egress of the adoptively transferred cells from the lungs.  
The optimal regional hyperthermia recruitment protocol identified by non-invasive imaging 
using 123I-scintigraphy was then further tested and validated in the context of NIS gene-based 
131I-therapy. Animals treated with MSC, hyperthermia, and 131I showed significantly reduced 
tumor growth and prolonged survival compared to the normothermic group and to the saline 
control group, demonstrating a significantly improved efficacy of MSC-mediated NIS gene 
therapy. The tumoral therapy response showed signs of a late divergence in tumor growth and 
survival curves, a phenomenon that has been described in immune therapy trials [123] as well 
in a phase III trial of neoadjuvant chemotherapy plus regional hyperthermia [124]. In our in vivo 
study, overall, we observed a heterogeneous response to hyperthermia therapy, with 4 out of 
8 hyperthermia-treated mice showing a clear therapeutic effect from significant reduction of 
tumor growth to partial remission. Heterogeneous response rates have also been seen in 
clinical hyperthermia trials, such as in the recent EORTC 62961-ESHO 95 phase III trial on 
neoadjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-
tissue sarcoma [124, 125].  We believe that a main reason for the heterogeneous response 
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may be our experimental setup for hyperthermia application using a conventional water bath 
with its limitations in establishing and monitoring stable and homogenous intratumoral 
temperatures. Several trials have demonstrated a strong correlation between intratumoral 
temperatures and response to treatment [126]. Recent technical improvements in the sources 
used to apply and measure heat have expanded the clinical use of hyperthermia. In this regard, 
a hybrid magnetic resonance-guided high-intensity focused ultrasound has been adapted for 
tumor hyperthermia therapy that allows a highly focused heating of the region with real-time 
temperature mapping and energy deposition [99]. 
 
3.6 Conclusion 
In our imaging-guided preclinical study, we were able to demonstrate significant stimulation of 
selective tumoral recruitment of genetically engineered MSCs by local hyperthermia 
application. Using NIS in its function as reporter gene, we were able to determine the optimal 
timing of hyperthermia treatment in the course of MSC application by non-invasive imaging 
that ultimately resulted in a significant therapeutic effect of CMV-NIS-MSC-based 131I therapy 
in liver cancer xenografts. These data open the promising prospect of using hyperthermia to 
enhance the effectiveness of MSC-mediated cancer gene therapy for future clinical application 
and of potential implementation of this strategy in other MSC-based therapy contexts such as 
regenerative medicine. 
 
3.7 Key points 
QUESTION: How is the recruitment of adoptively applied MSCs, engineered to express the 
theranostic NIS gene, to tumors altered in response to regional hyperthermia? 
PERTINENT FINDINGS: Regional heat-treatment of subcutaneous hepatocellular carcinoma 
(HuH7) xenograft tumors resulted in a significant stimulation of tumor-selective recruitment of 
genetically engineered MSCs analyzed by 123I-scintigraphy. Therapeutic 131I-application led to 
prolonged survival with reduced tumor growth.  
IMPLICATIONS FOR PATIENTS CARE: This translational study opens the prospect of 
combining the effects of regional hyperthermia with focused NIS gene therapy. 
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3.9 Supplementary Table 1 
 
 
  
Gene Forward primer (5´ -> 3´) Reverse primer (5´-> 3´) 
CXCL8 TCTGCAGCTCTGTGTGAAGG TTCTCCACAACCCTCTGCAC 
CXCL12 AGAGCCAACGTCAAGCATCT TAGCACAGCCTGGATAGCAA 
CCL15 CTGCTGCACCTCCTACATCT CATGCAATCCTGAACTCCCG 
FGF-2 GGAGAAGAGCGACCCTCAC AGCCAGGTAACGGTTAGCAC 
PDGF-β TTGGCTCGTGGAAGAAGG CGTTGGTGCGGTCTATGA 
PGF CATCCTGTGTCTCCCTGCTG GTCTCCTCCTTTCCGGCTTC 
TGF-β CAGCACGTGGAGCTGTACC AAGATAACCACTCTGGCGAGTC 
VEGF CTACCTCCACCATGCCAAGT ATGATTCTGCCCTCCTCCTT 
IGF-1 GCTGGTGGATGCTCTTCAGT TTGAGGGGTGCGCAATACAT 
TNFα CAGAGGGCCTGTACCTCATC GGAAGACCCCTCCCAGATAG 
TSP-1 TTGTCTTTGGAACCACACCA CTGGACAGCTCATCACAGGA 
HIF-1α GCTTTAACTTTGCTGGCCCC TTCAGCGGTGGGTAATGGAG 
NIS TGCTAAGTGGCTTCTGGGTTGT ATGCTGGTGGATGCTGTGCTGA 
SV40 TTGCTGTGCTTACTGAGGATG CCAATTATGTCACACCACAGA 
β-actin AGAAAATCTGGCACCACACC TAGCACAGCCTGGATAGCAA 
r18s CAGCCACCCGAGATTGAGCA TAGTAGCGACGGGCGGTGTG 
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4.1 Abstract 
Purpose: The tumor homing characteristics of mesenchymal stem cells (MSCs) make them 
attractive vehicles for the tumor-specific delivery of therapeutic agents, such as the sodium 
iodide symporter (NIS). NIS is a theranostic protein that allows non-invasive monitoring of the 
in vivo biodistribution of functional NIS expression by radioiodine imaging as well as the 
therapeutic application of 131I. To gain local and temporal control of transgene expression, and 
thereby improve tumor selectivity, we engineered MSCs to express the NIS gene under control 
of a heat-inducible HSP70B promoter. 
Experimental Design: NIS induction in heat-treated HSP70B-NIS-MSCs was verified by 125I 
uptake assay, RT-PCR, Western blot and immunofluorescence staining. HSP70B-NIS-MSCs 
were then injected i.v. into mice carrying subcutaneous hepatocellular carcinoma HuH7 
xenografts, and hyperthermia (1 hour at 41 °C) was locally applied to the tumor. 0 – 72 hours 
later radioiodine uptake was assessed by 123I-scintigraphy. The most effective uptake regime 
was then selected for 131I therapy. 
Results: The HSP70B promoter showed low basal activity in vitro and was significantly 
induced in response to heat. In vivo, the highest tumoral iodine accumulation was seen 12 
hours after application of hyperthermia. HSP70B-NIS-MSC-mediated 131I therapy combined 
with hyperthermia resulted in a significantly reduced tumor growth with prolonged survival as 
compared to control groups. 
Conclusions: The heat-inducible HSP70B promoter allows hyperthermia-induced spatial and 
temporal control of MSC-mediated theranostic NIS gene radiotherapy with efficient tumor-
selective and temperature-dependent accumulation of radioiodine in heat-treated tumors. 
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4.2 Graphical abstract 
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4.3 Introduction 
The sodium iodide symporter (NIS) is a transmembrane glycoprotein that actively co-transports 
two sodium and one iodide ion across the plasma membrane into the cytoplasm of thyroid 
follicular cells (reviewed in [16]). The ability to accumulate and store iodide is a characteristic 
of thyroid tissue and a prerequisite for thyroid hormone synthesis. This feature allows the 
efficient treatment/curing of thyroid cancer through the systemic administration of radioiodide 
[13].  NIS-expressing target cells absorb β-emitting radioisotopes, such as 131I or 188Re, and 
drive cell death via β-particulate radiation of the expressing cell and the neighboring tissues 
through bystander effects as the decaying particles have a path length of up to 2.4 mm in 
tissue. 
Genetically targeting NIS to non-thyroidal tumor tissues has opened the prospect of 
transferring standard clinical protocols for radioiodine imaging and therapy to a wide range of 
extra-thyroidal tumor entities [127]. Following cloning of the NIS gene in 1996 [24], initial 
experiments of ex vivo NIS gene transfer [25] and local NIS gene delivery by intratumoral 
injections have been described [26]. Subsequently, a series of diverse approaches have been 
evaluated for the systemic in vivo gene transfer into non-thyroidal tumors using viruses, 
nanoparticles or mesenchymal stem cells (MSCs) as carriers [27, 28, 30, 33-35, 39-41, 43-45, 
47-52, 128-131]. To this end, adoptively applied MSCs have been demonstrated to exhibit an 
innate tumor tropism and have been extensively studied as potential tumor-selective gene 
transfer vehicles including progressing to clinical studies [31, 32, 37, 54, 57, 72, 83, 85-87, 94, 
95, 120, 132-134]. Our group initially demonstrated the efficient transfer of functional NIS 
expression with accompanying therapeutic effects using MSCs transfected with NIS under the 
control of the constitutively active CMV-promoter [86]. As a next step, to reduce potential non-
tumor side effects by enhancing tumor-selective NIS expression, we studied the potential use 
of the tumor stroma-induced CCL5 (RANTES) gene promoter, which allowed a robust tumoral 
iodine accumulation in experimental tumors in mice leading to significantly reduced tumor 
growth and prolonged survival of the experimental animals after 131I and 188Re treatment [72]. 
To expand our strategies to include local as well as temporal control of NIS transgene induction 
and enhanced tumor selectivity of MSC-mediated NIS gene therapy, we engineered MSCs to 
express the NIS gene under control of a heat-inducible HSP70B promoter (HSP70B-NIS-
MSCs). 
Heat shock proteins (HSPs) are a heterogeneous group of molecular chaperones that includes 
the well-characterized 70-kDa HSP70 protein. The members of this family exhibit various 
cellular housekeeping and stress-related functions, such as the prevention of misaggregation, 
degradation, disaggregation and refolding of misfolded denatured proteins [135]. Their 
synthesis can be induced within minutes in response to stress, such as heat, through the 
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trimerization of heat shock factor-1 monomers that translocate to the nucleus where they bind 
to heat shock elements in target gene promoters, thereby activating a paused RNA polymerase 
II and allowing transcription to proceed (reviewed in [136]). 
Among the different heat-responsive promoters tested for gene therapy, the human HSP70B 
promoter was found to have a relatively low background activity and allow a rapid high level of 
heat-induced transgene expression in vitro and in vivo (reviewed in [137]). It was evaluated 
here as a candidate gene promoter for MSC-mediated NIS gene therapy. In the current study, 
we established and evaluated the use of a stable MSC line engineered with a heat-inducible 
HSP70B-NIS construct for enhanced control of tumor-specific NIS gene therapy.  
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4.4 Material and Methods 
Plasmid constructs and stable transfection of MSCs 
The plasmid construct pcDNA6.2ITRNEO-HSP70B-NIS, containing the full-length NIS gene 
(cDNA kindly provided by SM Jhiang, Ohio State University, Columbus, Ohio, USA) driven by 
the human HSP70B promoter, two sleeping beauty transposition sites and a geneticin 
resistance gene, was established as described previously [87] using the MultiSite Gateway 
Pro Plus Kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
Simian virus 40 large T antigen-immortalized human bone marrow-derived MSCs were used 
for the experiments as the immortalized MSCs have been previously shown to retain the 
multilineage differentiation capacity, morphology and surface antigen pattern of primary MSCs 
but show greater expansion potential as aging and senescence are switched off [138]. 
Transfection of MSCs was performed using the Neon Transfection System (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. Wild type MSCs (5 x 105 cells) were 
electroporated with a total of 3 µg plasmid (pcDNA6.2ITRNEO-HSP70B-NIS plus 
pCMV(CAT)T7-SB100X, containing a sleeping beauty transposon system [provided by Z Ivics, 
Max Delbrück Center for Molecular Medicine, Berlin, Germany)] with a pulse voltage of 1300 
Volt, a pulse width of 30 ms and a pulse number of 1. After 24 h incubation at 37 °C in a 
humidified CO2 incubator, selection medium was added containing 1% geneticin (G-418; 
Invitrogen, Carlsbad, California, USA). The clone showing the highest accumulation of 
radioiodide in an in vitro iodide uptake assay (see below), reflecting functional NIS expression, 
was used for further experiments (HSP70B-NIS-MSC). 
 
Cell Culture 
Cells were cultured in an incubator at 37 °C, with 5% (v/v) CO2 atmosphere and 95% relative 
humidity. The human hepatocellular carcinoma (HCC) cell line HuH7 (JCRB0403; Japanese 
Collection of Research Bioresources Cell Bank, Osaka, Japan) was grown in Dulbecco’s 
Modified Eagle Medium (1 g/l glucose; Sigma Aldrich, St. Louis, Missouri, USA) supplemented 
with 10% (v/v) fetal bovine serum (FBS; FBS Superior, Biochrom GmbH, Berlin, Germany) and 
100 U/ml penicillin and 100 µg/ml streptomycin (P/S; Sigma-Aldrich). The human MSC line 
(HSP70B-NIS-MSC) was cultured in Roswell Park Memorial Institute (RPMI)-1640 culture 
medium (Sigma-Aldrich) enriched with 10% FBS, P/S and G-418. 
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In vitro heat treatment 
For the in vitro hyperthermia experiments, the cell culture dishes were sealed and the cells 
were exposed to heat at different temperatures ranging from 39 to 42 °C in a water bath for 30 
to 60 min and then maintained in an incubator at 37 °C for 4 to 48 h. 
 
125I uptake assay 
NIS-mediated uptake of 125I in HSP70B-NIS-MSCs was measured as described previously 
[116, 139]. Briefly, cells were seeded on 12-well plates and iodide uptake studies were 
performed at different time points (0 – 24 h) after heat treatment. Cells were incubated in 
Hanks' Balanced Salt solution (Gibco/Life Technologies, Carlsbad, California, USA), 
complemented with 10 µM NaI, 100 000 counts per minute (cpm) of Na125I/ml (PerkinElmer, 
Waltham, Massachusetts, USA) and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES; Sigma) (pH 7.3) for 45 min. The NIS-specific inhibitor KClO4 (100 mM; Merck 
Millipore, Burlington, Massachusetts, USA) was added to control wells to verify NIS specificity 
of uptake. After washing, cells were lysed in 1 N NaOH (Carl Roth GmbH + Co KG, Karlsruhe, 
Germany) for 15 min and trapped 125I was analyzed by γ-counting (Beckman Coulter GmbH, 
Krefeld, Germany). Results were normalized to cell survival (see below) and expressed as 
cpm / A620. 
 
Cell viability assay 
The commercially available MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay (Sigma Aldrich) was performed following the manufacturer’s instructions. The 
absorbance of the resulting formazan product was measured on a Sunrise microplate 
absorbance reader (Tecan, Männedorf, Switzerland) at a wavelength of 620 nm using the 
software Magellan (Tecan). 
 
Quantitative real-time PCR 
Total RNA of the heat treated and control HSP70B-NIS-MSCs was isolated 0 – 48 h after 
thermo-stimulation using the RNeasy Mini Kit with QIAshredder (Qiagen, Venlo, Netherlands) 
according to the manufacturer’s recommendations. Single stranded cDNA was generated 
using Superscript III reverse transcriptase (Invitrogen). Quantitative real-time PCR (RT-PCR) 
was performed using the SYBR green PCR master mix (Qiagen) in a Mastercycler ep gradient 
S PCR cycler (Eppendorf, Hamburg, Germany). The following primers were used: SLC5A5 
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(hNIS) (5´-TGCGGGACTTTGCAGTACATT-3´) and (5´-TGCAGATAATTCCGGTGGACA-3´), 
HSPA1A (5´- GATCAACGACGGAGACAAGC-3´) and (5´-GCTGCGAGTCGTTGAAGTAG-
3´), HSPA7 (5´-TTCCATGAAGTGGTTCACGA-3´) and (5´-TTGACGCTGGTGTCTTTGAG-
3´), and ACTB (β-actin) (5´-AGAAAATCTGGCACCACACC-3´) and (5´-
TAGCACAGCCTGGATAGCAA-3´). Levels of cDNA were normalized to the internal control β-
actin. Relative expression levels were calculated using comparative ΔΔ-Ct values. 
 
Membrane preparation and Western blot 
Membrane proteins from heat-treated and control cells were extracted as described previously 
[116] and protein concentration measured by Bradford assay (BioRad Laboratories Inc., 
Hercules, California, USA). Western blot analysis was conducted as reported previously [116], 
using a mouse monoclonal NIS-specific antibody (Merck Millipore; dilution 1:1700) overnight 
at 4 °C and a horse-radish peroxidase-labeled goat anti-mouse antibody (Jackson 
ImmunoResearch Europe Ltd., Ely, UK; dilution 1:2000) for 1 h at room temperature. After 1 
min incubation with enhanced chemiluminescence Western blotting detection reagent 
(WESTAR ETA C 2.0; Cyanagen Srl, Bologna, Italy), images were taken with an ECL 
ChemoCam Imager (INTAS, Göttingen, Germany). As control for protein loading, the 
membrane was stripped (Restore Western Blot Stripping Buffer, Thermo Fisher Scientific) and 
re-probed with a monoclonal anti-β-actin antibody produced in mouse (Sigma Aldrich; dilution 
1:1500). The intensity of the bands was measured by densitometry using ImageJ software 
(NIH, Bethesda, Maryland, USA) and normalized to the β-actin loading control, expressed as 
the relative amount of NIS protein. 
 
Immunofluorescence staining 
HSP70B-NIS-MSCs were seeded directly on FBS-coated microscope slides and grown until 
60% confluent. 6 h after hyperthermia, the slides were air-dried overnight at room temperature 
and monolayers fixed with 80% methanol (Carl Roth) for 5 min at 4 °C, followed by 100% 
acetone (Carl Roth) for 2 min at -20 °C. Following blocking with 12% bovine serum albumin 
(Sigma-Aldrich) in phosphate-buffered saline (PBS; Sigma Aldrich) for 30 min, cells were then 
incubated with a primary mouse monoclonal NIS-specific antibody (Merck Millipore; dilution 
1:500) for 90 min. A secondary Cy3 AffiniPure donkey anti-rabbit IgG antibody (Jackson 
ImmunoResearch; dilution 1:400) and bisbenzimide (Hoechst; Sigma Aldrich; dilution 1:2000) 
to counterstain nuclei were added for 30 min. Pictures were taken using an Axiovert 135 TV 
fluorescence microscope in combination with an AxioCam MRm CCD camera and the 
AxioVision Rel. 4.8 software (Carl Zeiss Microscopy GmbH, Jena, Germany). 
Hyperthermia-inducible MSC-mediated NIS Gene Therapy 
44 
 
Establishment of subcutaneous HuH7 xenografts 
5 – 6 week old female CD1 nu/nu mice were bought from Charles River (Sulzfeld, Germany) 
and kept under specific pathogen-free conditions with ad libitum access to water and mouse 
chow. The regional governmental commission for animals (Regierung von Oberbayern, 
Munich, Germany) authorized all experimental protocols.  
Subcutaneous (s.c.) tumors were established by s.c. injection of 5 x 106 HuH7 cells re-
suspended in 100 µl PBS into the right flank region of the animals. Tumor volumes were 
determined using a caliper and calculated by the equation height x length x width x 0.52. When 
the tumor reached a volume > 1500 mm3 or showed signs of necrosis, mice were sacrificed. 
 
In vivo regional hyperthermia 
For regional hyperthermia treatment in vivo, mice were anesthetized with inhalation isoflurane 
narcosis and placed on a water bath covered with a plastic plate that was specifically designed 
to allow only the tumor bearing leg to be submerged into the water through holes in the plastic 
cover. A rectal thermometer (Homeothermic Blanket Systems with Flexible Probe; Harvard 
Apparatus, Massachusetts, USA) monitored body temperature. 
 
Non-invasive monitoring of in vivo NIS biodistribution 
As soon as tumors reached a volume of approximately 500 mm3, 5 x 105 HSP70B-NIS-MSCs 
were injected systemically via the tail vein every second day for a total of three times. 3 days 
later, regional hyperthermia was applied (41 °C or, as control, 37 °C for 1 h). The mice received 
18.5 MBq (0.5 mCi) of 123I (GE Healthcare Buchler GmBH & Co. KG, Braunschweig, Germany) 
intraperitoneally (i.p.) after 0, 6, 12, 18, 24, 36, 48, and 72 h and gamma camera imaging 
(e.cam, Siemens, Munich, Germany) was performed using a low-energy, high-resolution 
collimator. Intrinsic thyroidal iodide uptake was reduced by the addition of 5 mg/ml L-thyroxine 
(L-T4; Sigma Aldrich) to the drinking water ten days before 123I administration. Using the 
HERMES GOLD (Hermes Medical Solutions, Stockholm, Sweden) software, regions of interest 
were evaluated and tumoral iodide uptake was calculated and expressed as percentage of 
injected dose (ID) per tumor (% ID/tumor). Using the Medical Internal Radiation Dose (MIRD) 
concept, dosimetry was calculated with a RADAR dose factor (www.doseinfo-radar.com). 
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Ex vivo immunohistochemical NIS protein staining 
Paraffin-embedded tumor sections and a series of control organs from the mice used for 123I-
scintigraphy were immunohistochemically stained as described previously [117]. Staining was 
performed using a primary mouse monoclonal NIS-specific antibody (Merck Millipore; dilution 
1:500) for 90 min followed by a biotin-SP-conjugated goat anti-mouse IgG antibody (Jackson 
Immunoresearch; dilution 1:200) for 20 min and then peroxidase-conjugated streptavidin 
(Jackson Immunoresearch; dilution 1:300) for an additional 20 min. Immunohistochemically 
stained tumor sections were scanned using the Pannoramic MIDI digital slide scanner and 
pictures taken with Caseviewer software (3DHISTECH Ltd., Budapest, Hungary) and control 
organs were imaged on an Olympus BX41 microscope equipped with an Olympus XC30 CCD 
camera (Olympus, Shimjukum Tokio, Japan). 
 
Ex vivo mRNA expression analysis 
Frozen tumor sections of the 123I-scintigraphy were shredded using 20G and 25G syringes and 
RNA was isolated using the RNeasy Mini Kit with QIAshredder (see above). RT-PCR was run 
on a Lightcycler 96 System (Roche, Basel, Switzerland) and levels of cDNA were normalized 
to the mean of the internal controls β-actin, r18s and UBC. In addition to NIS, the primers r18s 
(5´-CAGCCACCCGAGATTGAGCA-3´) and (5´-TAGTAGCGACGGGCGGTGTG-3´) and UBC 
(5´-ATTTGGGTCGCGGTTCTTG-3´) and (5´-TGCCTTGACATTCTCGATGGT-3´) were used. 
 
131I-therapy study 
Therapy trials were started when tumors had an average size of 5 x 5 mm. Ten days before 
radioiodide injection, drinking water of mice was supplemented with L-T4 and standard mouse 
chow was switched to a low iodine diet (ssniff Spezialdiäten GmbH, Soest, Germany) to reduce 
radioiodine uptake by the thyroid gland and enhance potential tumoral iodine accumulation. 
Animals were randomly assigned to four treatment groups. HSP70B-NIS-MSCs were injected 
intravenously (i.v.) three times on every second day, followed by hyperthermia application 72 
h later. 12 – 18 h after the heat treatment, 55.5 MBq (1.5 mCi) 131I (GE Healthcare) were 
injected i.p. This cycle was repeated 24 h after 131I administration, for a total of three times, 
with the second and third cycle consisting of only one MSC injection to reduce therapy duration 
(therapy group: HSP70B-NIS-MSCs + 41 °C + 131I; n = 9). To investigate the potential direct 
effects of hyperthermia on MSCs, we used saline instead of 131I (NaCl; Fresenius Kabi, Bad 
Homburg, Germany; HSP70B-NIS-MSCs + 41 °C + NaCl; n = 7). In an additional control group, 
MSCs and radioiodide were replaced by saline (NaCl + 41 °C + NaCl; n = 10) to investigate 
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the potential effects of hyperthermia alone. As controls, the therapy schemes as described 
above were also conducted with 37 °C instead of 41 °C (HSP70B-NIS-MSCs + 37 °C + 131I; n 
= 10,  HSP70B-NIS-MSCs + 37 °C + NaCl; n = 8, and NaCl + 37 °C + NaCl; n = 9). The tumor 
volume of the mice was estimated as described above and mice were sacrificed when the 
tumor volume exceeded 1500 mm3. 
 
Ex vivo immunofluorescence assay 
Immunofluorescence staining on dissected frozen tissue samples of HuH7 tumors and 
quantitative analysis of cellular proliferation (Ki67; Abcam, Cambridge, UK; dilution 1:200) and 
blood vessel density (CD31; BD Pharmingen, Heidelberg, Germany; dilution 1:100) were 
performed according to the protocol described previously [51]. Pictures were taken using a 
Leica DMI6000B microscope equipped with a Leica DFC365 FX camera and Leica MM AF 
software (Leica Microsystems GmbH, Wetzlar, Germany). Quantification of six visual fields per 
tumor section was performed using ImageJ software. 
 
Statistical analysis 
All in vitro experiments were performed at least in triplicate and results are reported as mean 
± standard error of the mean (SEM), mean fold change ± SEM or in percent. Statistical 
significance was tested by two-tailed Student’s t-test , one-way analysis of variance (ANOVA) 
followed by post-hoc Tukey (honestly significant difference) test for comparison of more than 
two groups, two-way ANOVA followed by post-hoc Tukey test for the repeated measurements 
in the imaging study, or by log-rank for Kaplan-Meier survival plots. p values < 0.05 were 
considered significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
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4.5 Results 
 
Figure 12 In vitro radioiodide uptake studies of HSP70B-NIS-MSCs. HSP70B-NIS-MSCs were heat-treated in 
a water bath at temperatures ranging from 39 to 42 °C for 60 min, or as control at 37 °C, and functional NIS 
expression was analyzed by an in vitro iodide uptake assay (A). 125I uptake assay was performed at different time 
points (0 – 24 h) after promoter activation by heating the cells at 41 °C for 60 min (B). Cell viability after thermo-
stimulation was analyzed by MTT assay (C + D). The NIS-specific inhibitor perchlorate was added to control the 
NIS dependency, analyzed 4 h after hyperthermia treatment and compared to unheated HSP70B-NIS-MSC control 
cells (E). Data are represented as mean ± SEM (n = 3; one way ANOVA analysis; *p < 0.05; **p < 0.01; ***p < 
0.001). 
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In vitro radioiodide uptake studies of HSP70B-NIS-MSCs 
Radioiodide uptake assays were performed to verify functional NIS expression by HSP70B-
NIS-MSCs. The HSP70B promoter showed a low basal activity (no 125I uptake above 
background levels of unheated HSP70B-NIS-MSCs control cells) in vitro but showed a 
significantly induced expression in response to heat. Testing a temperature range from 39 to 
42 °C, we observed the strongest radioiodine accumulation at 41 °C (Figure 12 A). HSP70B-
NIS-MSCs tolerated temperatures up to 41 °C well, but showed reduced viability yielding 71% 
viable cells at 42 °C (Figure 12 C). In addition to temperature-dependence of NIS induction, 
we also characterized the time dependence of functional iodide uptake. The induction of 125I 
accumulation was found to occur rapidly after heat exposure with a maximum level reached 
as early as 4 h after hyperthermia application showing a 46-fold induction of iodide uptake as 
compared to unheated HSP70B-NIS-MSC-control cells (Figure 12 B). The increase in iodide 
accumulation activity displayed a plateau with high uptake levels remaining for up to 15 h after 
heat-induced promoter activation. No significant change in cell viability was observed in 
response to heat in this time frame (Figure 12 D). As a control, the iodide uptake was shown 
to be sensitive to the NIS-specific inhibitor perchlorate, demonstrating NIS dependency 
(Figure 12 E). 
 
In vitro NIS mRNA and protein levels of HSP70B-NIS-MSCs 
Parallel analysis of NIS mRNA levels by RT-PCR (Figure 13 A) confirmed heat-induced and 
time-dependent NIS expression with the highest mRNA levels measured 4 h after heat 
treatment. Induction of mRNA expression of endogenous HSPs HSP70 (HSPA1A) (Figure 13 
B) and HSP70B (HSPA7) (Figure 13 C) occurred in the same time frame as that seen for the 
NIS transgene. Western blot analysis showed a similar pattern of NIS protein expression with 
maximum protein levels seen 8 h after thermo-stimulation (Figure 13 D). In addition, validation 
using immunofluorescence staining showed significant NIS-specific immunofluorescence in 
HSP70B-NIS-MSCs after hyperthermic treatment whereas only weak immunoreactivity was 
observed in non-heated, control HSP70B-NIS-MSCs, and no expression was seen in wild type 
MSCs (Figure 13 E). 
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Figure 13 In vitro NIS mRNA and protein levels of HSP70B-NIS-MSCs. RT-PCR analysis of mRNA extracted 
from heat-treated (60 min at 41 °C) and unheated HSP70B-NIS-MSCs after 0 – 48 h, using primers for NIS 
(SLC5A5) (A), the endogenous HSP70 (HSPA1A) (B) and HSP70B (HSPA7) (C). Results were normalized to β-
actin (ACTB), heat-treated compared to unheated MSCs for each time point and expressed as the mean ± SEM (n 
= 3; two-tailed Student’s t test; *p < 0.05; **p < 0.01). NIS protein levels were assessed by Western blot (D), 
extracted by membrane isolation at 4 – 48 h after thermo-stimulation or, as controls, of unheated HSP70B-NIS-
MSCs. The intensity of the bands was measured by densitometry and normalized to the β-actin loading control. 
NIS-specific immunofluorescence staining (red) of heat-treated HSP70B-NIS-MSCs (bottom row), unheated 
HSP70B-NIS-MSCs (middle row), and unheated wild-type MSCs (top row) seeded and fixated on coverslips (E). 
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Radioiodide biodistribution in vivo after MSC-mediated NIS gene transfer 
By placing a thermo probe intratumorally, we confirmed rapid, stable and sufficient tumoral 
temperature (41.0 ± 0.1 °C or, as control, 37.0 ± 0.1 °C respectively) delivery, while the body 
temperature of the mice stayed within physiological levels [data not shown]. Following these 
studies, subsequent analyses were conducted without the invasive tumoral probe, which could 
distort results as the wound caused by the probe could potentially influence MSC recruitment. 
After three HSP70B-NIS-MSCs injections, tumor-bearing mice were heat-treated regionally for 
1 h at 41 °C, to activate the heat-inducible HSP70B promoter, or as control at 37 °C. 0 to 72 h 
later, 18.5 MBq 123I were administrated and functional NIS expression was analyzed by gamma 
camera imaging. The images of the 123I-scintigraphy revealed the strongest tumoral iodine 
accumulation, mediated by functional NIS, in animals with a latency of 12 h (Figure 14 C) 
between hyperthermia and radioiodine injection, whereas mice in the 37 °C control group 
(Figure 14 F) exhibited the weakest signal. Quantitative analysis of serial scanning (Figure 14 
G) showed no difference to 37 °C control levels (maximum of tumoral iodide uptake 1 h post 
123I injection [Figure 14 H]: 37 °C control 6.83 ± 1.99% ID/tumor) when radioiodine was injected 
directly after thermo-stimulation (Figure 14 B, G-H; 0 h 7.78 ± 1.30% ID/tumor). However, a 
slight increase of tumoral iodine accumulation was observed (Figure 14 G-H; 8.58 ± 1.86% 
ID/tumor) when there was a period of 6 h between hyperthermia and 123I injection. Significantly 
increased and maximal radioiodine levels were reached at the 12 h interval between promoter 
activation by heat treatment and radioiodide administration (Figure 14 C,G-H; 9.77 ± 2.33% 
ID/tumor) with a plateau up to 18 h (Figure 14 G-H; 9.41 ± 0.86% ID/tumor). All other groups, 
with a gap of 24 h (Figure 14 D,G-H;7.78 ± 0.85% ID/tumor), 36 h (Figure 14 G-H; 7.99 ± 
2.22% ID/tumor), 48 h (Figure 14 G-H; 6.79 ± 0.79% ID/tumor) and 72 h (Figure 14 E,G-H; 
6.96 ± 1.18% ID/tumor) between HSP70B stimulation and imaging exhibited a similar iodine 
uptake as the control group. Physiological radioiodide accumulation in the thyroid and salivary 
glands (SG), stomach and, due to renal elimination of 123I, in the urinary bladder, was visible 
in all animals (Figure 14 B-F). Dosimetric calculations revealed a higher tumor-absorbed dose 
of 70 ± 28 mGy/MBq/g tumor and an effective half-life of 3.6 h for 131I in heat-treated animals 
with the 12 h interval, as compared to the unheated control group with 44 ± 15 mGy/MBq/g 
tumor-absorbed dose and a calculated effective half-life of 3.2 h for 131I. 
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Figure 14 Radioiodide biodistribution in vivo after MSC-mediated NIS gene transfer. In vivo, using the 
hepatocellular carcinoma (HuH7) xenograft mouse model, HSP70B-NIS-MSCs were injected into the tail vein of 
mice, followed by hyperthermia, or as controls normothermia at 37 °C, 3 days later. 0 – 72 h after promoter activation 
by thermo-stimulation, 18.5 MBq 123I were injected and serial gamma camera imaging started (A). Images of gamma 
camera imaging taken 2 h after radioiodide of animals with 0 h (B; n = 7), 6 h (n = 5), 12 h (C; n = 7), 18 h (H; n = 
4), 24 h (D; n = 6), 36 h (n = 4), 48 h (n = 5) and 72 h (E; n = 4) between promoter activation by hyperthermia and 
radioiodine injection and control animals, treated at 37 °C (F; n = 5) (one representative image for each treatment 
group). Quantification of serial 123I-scintigraphy (G) representing the efflux of the injected 123I and comparison of the 
tumoral 123I accumulation 1 h post injection (H) (the blue line represents the controls at 37 °C). Results are 
expressed as mean ± SEM; two-way ANOVA with post-hoc Tukey test *p < 0.05. 
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Ex vivo analysis of NIS expression 
Paraffin-embedded tissue sections derived from HuH7 xenografts after 123I-scintigraphy were 
stained immunohistochemically using a monoclonal NIS antibody. Tumor sections from control 
animals (37 °C; Figure 15 A) showed much less perivascular human NIS-specific 
immunoreaction (red) as did the group of thermo-stimulated animals (41 °C, 12 h gap; Figure 
15 B). Control organs (liver, lungs, spleen and kidney) of heat-treated (Figure 15 C) and 
control animals (Figure 15 D) did not show NIS-specific immunoreactivity. Frozen tumor 
sections were processed for mRNA isolation. RT-PCR showed an upregulation of NIS (Figure 
15 E), as well as the endogenous HSPs, HSP70 (Figure 15 F) and HSP70B (Figure 15 G) in 
a temperature- and time-dependent fashion as an additional confirmation of the functional NIS 
expression as well as the efficient heat transfer to the tumors. 
 
MSC-mediated NIS gene therapy in vivo 
Following validation of functional NIS expression by non-invasive radioiodine imaging, a 
therapy trial with 131I was initiated based on the approach that showed optimal tumoral iodine 
accumulation as seen by the 123I-scintigraphy. After three MSC administrations, radioiodine 
was injected 12 to 18 h after hyperthermic treatment to be within the plateau phase as seen in 
vitro and by gamma camera imaging. This cycle was repeated for a total of three times, but 
cycle two and three consisted of only one MSC application to reduce the overall length of the 
treatment scheme (Figure 16 A). Mice injected with saline only with (41 °C) (NaCl + 41 °C + 
NaCl) or without hyperthermia (37 °C) (NaCl + 37 °C + NaCl), and mice receiving saline instead 
of 131I with (41 °C)(HSP70B-NIS-MSCs + 41 °C + NaCl) and without hyperthermia (37 °C) 
(HSP70B-NIS-MSCs + 37 °C + NaCl), served as controls and exhibited an uninterrupted and 
exponential tumor growth (Figure 16 B and Supplementary Figure 1). Mice treated with 
HSP70B-NIS-MSCS and 131I following hyperthermia at 41 °C (HSP70B-NIS-MSCs + 41 °C + 
131I) exhibited a significantly reduced tumor growth as compared to all control groups, which 
was associated with prolonged survival of the mice (Figure 16 C). In one mouse, an impressive 
partial remission was observed with tumor shrinkage from 410 mm3 to 28 mm3 until day 78. As 
compared to the saline control groups, survival analysis also revealed a significantly prolonged 
survival of mice treated with HSP70B-NIS-MSCs of up to 78 days after therapy start in the 
hyperthermia group (HSP70B-NIS-MSCs + 41 °C + 131I) and up to 40 days (HSP70B-NIS-
MSCs + 37 °C + 131I) in the normothermic group. At day 22 after the start of therapy, all animals 
within the NaCl + 41 °C + NaCl group had to be sacrificed based on tumor growth, whereas 
100% of the HSP70B-NIS-MSCS + 41 °C + 131I and 70% of the HSP70B-NIS-MSCS + 37 °C 
+ 131I groups were still alive. By day 26, all animals in the saline control groups had reached 
the endpoint criteria. 
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Figure 15 Ex vivo analysis of NIS expression. NIS-specific immunohistochemistry (red) was performed on 
paraffin-embedded HuH7 tumor sections. Tumors of mice of 37 °C controls (A) compared to mice which were heat-
treated with a 12 h latency between promoter activation and 123I administration (B). Control organs (liver, lung, 
spleen and kidney) of mice receiving 37 °C (C) or 41 °C (D) treatment. One representative image is shown each at 
2x – 73x magnification for tumor sections and 20x for control organs. mRNA was isolated from frozen tumors 
sections of heat treated mice (groups in which 0, 12, 18, and 36 h were in between promoter activation and start of 
123I-scintigraphy) and controls (37 °C) at the end of the serial gamma camera imaging and analyzed for NIS (E), 
endogenous HSPA1A (F) and HSPA7 (G) by RT-PCR (n = 4; one-way ANOVA; *p < 0.05, ***p < 0.001). 
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The median survival after therapy start for the therapy group HSP70B-NIS-MSC + 41 °C + 131I  
was 31 days, for the HSP70B-NIS-MSCS + 37 °C + 131I 25 days, for NaCl + 41 °C + NaCl 
treated animals 13 days, and for the NaCl + 37 °C + NaCl group 17 days. The treated mice 
showed no major adverse effects of radionuclide treatment and were sacrificed due to tumor 
load, only one mouse due to respiratory problems on day 78 after therapy start. 
 
Figure 16 Heat-induced MSC-mediated NIS gene therapy in vivo. Three days after systemic injections of 
HSP70B-NIS-MSCs (black arrows), hyperthermia (red arrows) was administered to mice harboring HuH7 xenograft 
tumors. 12 to 18 h later, 55.5 MBq of therapeutic 131I (green arrows) was applied. This treatment cycle was repeated 
for a total of three times (A). Tumor growth (B) and overall survival (C) were evaluated for the treatment with 
HSP70B-NIS-MSCs, hyperthermia and 131I (HSP-NIS-MSCs + 41 °C + 131I; n = 9), compared to control groups, 
receiving hyperthermia and saline (NaCl + 41 °C + NaCl; n = 10) and to normothermic groups (HSP70B-NIS-MSCs 
+ 37 °C + 131I; n = 9 and NaCl + 37 °C + NaCl; n = 10). Results are expressed as mean ± SEM (one-way ANOVA 
for tumor growth and log-rank test for log-rank for Kaplan-Meier survival plots; *p < 0.05; **p < 0.01; ***p < 0.001). 
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Ex vivo proliferation and blood vessel density analysis 
At the end of the observation period, the tumors were dissected and frozen tumor sections 
were stained using an antibody to identify blood vessels (CD31; red) and a Ki67-specific 
antibody to display general cell proliferation (green) (Figure 17 A-D). Tumors treated with 
HSP70B-NIS-MSCs, radioiodide and hyperthermia (HSP70B-NIS-MSCs + 41 °C + 131I) 
(Figure 17 A) showed a significantly lower proliferation index as did the saline control groups 
(Figure 17 E), as well as a significantly lower blood vessel density compared to all three control 
groups (Figure 17 F), thereby demonstrating an antiangiogenic effect and thus further 
validating successful HSP70B-NIS-MSC-mediated 131I therapy. 
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Figure 17 Reduced ex vivo proliferation and blood vessel density as result of heat-induced MSC-mediated 
NIS gene therapy. Ki67 [(E); green; proliferation index] and CD31 [(F); red; labeling blood vessels] 
immunofluorescence staining of frozen tumor sections was performed on tumors derived from mice receiving 
HSP70B-NIS-MSCs at the end of the 131I therapy (A; n = 9), unheated controls (B; n = 9) and mice receiving saline 
with (C; n = 10) or without (D; n = 9) heat treatment instead of MSCs. Nuclei were counterstained with Hoechst 
(blue). One representative image is shown each at 10x magnification. Results are expressed as mean ± SEM (one-
way ANOVA; *p < 0.05; ***p < 0.001).  
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4.6 Discussion 
When used as a theranostic gene, the symporter NIS acts as an effective molecular reporter 
gene with robust therapeutic options, thus enabling the visualization and treatment of tumors 
through the application of appropriate radionuclides. NIS efficiently transports various 
radionuclides, allowing the application of easily available and extensively studied radionuclides 
such as 123I, 124I, 18F-tetrafluoroborate or 99mTc for in vivo imaging of functional NIS expression, 
and 131I, 188Re, or 211At for the delivery of therapeutic applications (summarized in [15, 20, 140]). 
The treatment of thyroid cancer with 131I has been performed in the clinic with great success 
since 1946 with a well-understood safety profile and is still the most preferred treatment 
modality, after thyroidectomy, for differentiated thyroid cancer [13]. The potential use of 
exogenously applied NIS to induce radioiodine accumulation in non-thyroidal tumors has been 
investigated in a variety of in vitro and in vivo tumor models, such as anaplastic thyroid cancer 
[29], glioma [30], acute myeloid leukemia [131], multiple myeloma [27], cancer of the prostate 
[26, 38-41], the liver [31], the colon [32, 33], the breast [34], and the pancreas [35-37] by 
several groups including our own. These very promising proof-of-principle studies have led to 
phase I/II clinical studies with NIS as a reporter gene and / or therapy gene using virus-
mediated NIS gene delivery for locally recurrent prostate cancer (NCT00788307), multiple 
myeloma (NCT00450814, NCT02192775, NCT03017820) and for various other non-thyroidal 
cancer types (NCT01503177, NCT01846091, NCT02364713, NCT02700230, NCT02919449, 
NCT02962167, NCT03120624, NCT03171493, NCT03647163) [141-144]. 
The ultimate goal of tumor gene therapy is the efficient delivery of a transgene by the use of 
systemically applied vectors. To this end, engineered versions of MSCs represent attractive 
candidates as gene delivery vehicles [120]. MSCs are actively recruited to sites of tissue 
injuries or chronic inflammation and contribute to tissue remodeling [145]. The body sees 
“tumors as wounds that do not heal” [64, 65] and for this reason it drives the mobilization of 
MSCs from various tissue stores and their subsequent migration to developing tumor stroma 
[80, 146]. MSCs exhibited selective incorporation into growing tumor stroma [63, 67] driven by 
high local concentrations of inflammatory chemokines and cytokines secreted by the tumor 
and the tumor stroma [112, 147]. This tumor tropism of MSCs has been used as a “Trojan 
Horse”-like therapy approach in which genetically engineered MSCs deliver a therapeutic 
agent, in our case the NIS gene, deeply into growing tumors [31, 32, 37, 72, 78, 79, 86-88, 94, 
95, 148]. The adaption of engineered MSCs as a therapeutic approach to treat solid cancers 
using NIS has proceeded towards clinical application with the initiation of a first series of phase 
I/II trials using measles virus (MV)-NIS transfected MSCs in recurrent ovarian cancer 
(NCT02068794).  In addition, a clinical trial using MSCs as gene delivery vehicles based on 
our previous work was completed using MSCs modified with CCL5-driven HSV-TK for the 
treatment of gastrointestinal cancer [85]. In additional clinical trials, researchers are evaluating 
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IFN-β expressing MSCs in ovarian cancer (NCT02530047) at MD Anderson Cancer Center, 
and the safety and anti-tumor capacity of TRAIL-modified MSCs in metastatic non-small cell 
lung cancer (NCT03298763) at University College London Hospital.  
While MSCs show significant tumor tropism, a portion of the adoptively applied MSCs 
potentially also home to normal tissues, such as the spleen or the lung [72]. Therefore, 
selective control of the expression of the transgene provides a means of limiting potential 
damage to non-tumor tissues. Our group has demonstrated that this can be achieved by using 
specific gene promotors linked to signals or differentiation pathways that occur mostly or only 
within the tumor setting. We have previously shown that MSCs expressing NIS under control 
of the tumor stroma-specific RANTES/CCL5 promoter [72], a HIF-1α-driven synthetic promoter 
activated by tumor hypoxia [31], or using a synthetic promoter responsive to transforming 
growth factor B1 (TGFB1) present in the tumor setting [87] can lead to a robust and efficient 
NIS expression within tumors. In these settings, the biodistribution of our genetically 
engineered MSCs was analyzed by 123I-scintigrahy or 124I- and 18F-TFB PET-imaging, using 
NIS as reporter gene. The subsequent systemic application of 131I was shown for each 
approach to result in a significant reduction in tumor growth and a prolonged survival of the 
animals, thus demonstrating both the great potential of NIS as a theranostic gene and the 
potential benefit of engineered MSCs as therapy vehicles. External beam radiation was 
recently found to efficiently enhance MSC recruitment to treated tumors as well as to strongly 
increase tumor levels of TGFB1 [94]. Using a TGFB1-inducible SMAD-responsive promoter 
for MSC-mediated NIS gene therapy in combination with external beam radiation dramatically 
increased the therapeutic efficacy of NIS gene therapy with complete tumor remission seen in 
a subset of mice [95]. 
The present study builds on these results to evaluate a potentially more precise means of 
controlling theranostic transgene expression through the use of the heat-inducible HSP70B 
promoter that was shown here to confer local and temporal control of strong and robust 
induction of transgene expression. The HSP70B (HSPA7) gene was discovered in 1985 [149], 
is encoded near the highly homologous HSP70B´ (HSPA6) on chromosome 1 [150], and, 
although mRNA is expressed after thermo-stimulation, it does not appear to encode a 
functional protein [151]. 
The heat-inducible HSP70B promoter was selected for use in our MSC-mediated NIS gene 
transfer approach. In vitro characterization of HSP70B-NIS-MSCs demonstrated a time- and 
temperature-dependent NIS-mediated iodine accumulation. The HSP70B promoter showed 
only background expression before heat was applied, but was significantly induced allowing a 
more than 45-fold functional NIS response to 60 min of heat treatment at 41 °C. NIS expression 
reached a maximum by 6 to 8 h after thermo-stimulation that was confirmed at mRNA and 
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protein levels by RT-PCR, Western blot and NIS-specific immunofluorescence, respectively. 
These results are in line with previous studies that used the HSP70B promoter, where a similar 
pattern of temperature- and time-dependent promoter activity was observed in vitro [152-155]. 
We could validate these findings in an in vivo HCC xenograft mouse model using 123I-
scintigraphy imaging studies that revealed a pattern of time-dependent tumoral iodine uptake, 
mediated by NIS, in vivo that closely matched our in vitro results. The strongest iodine uptake 
in vivo was found 12 h after hyperthermia treatment that was only slightly later than that seen 
in the cell culture studies (6 – 8 h after promoter activation). As seen with other HSP proteins 
that are often increased in tumor settings without thermo-stimulation due to the proteotoxic 
stressful conditions that cancer cells face, including nutrient deprivation, the presence of free 
reactive oxygen species, hypoxia, acidosis and high levels of mutant proteins [156, 157], the 
HSP70B promoter (HSP70B-NIS-MSC) showed increased basal activity within the tumor 
microenvironment in vivo as evidenced by gamma camera images in the 37 °C control group. 
This parallels the observation that HSP70 is typically found to be increased in tumors [158] 
and is currently evaluated as tumor-specific diagnostic and therapeutic target [159]. 
Importantly, the HSP70B-NIS-MSCs were not found to be activated in non-target organs 
(Figure 15 C + D). 
Therapy using hyperthermia and 131I led to a strongly reduced tumor growth, prolonged survival 
with reduced blood vessel density and proliferation index, demonstrating the long-term 
antiangiogenic therapeutic efficacy of 131I. At normothermic conditions (37 °C), treatment with 
HSP70B-NIS-MSCs followed by 131I application resulted in slightly reduced tumor growth (22% 
showed a response to the therapy). HSP70B-NIS-MSCs, 131I and hyperthermia (41 °C) 
treatment resulted in a robust and significant therapeutic effect with reduced tumor growth in 
67% of the animals, and a partial tumor remission in one animal. Hyperthermia and MSCs 
alone (HSP70B-NIS-MSCs + 41 °C + NaCl) showed no difference in survival or tumor growth 
(Supplementary Figure 1 A + B) compared to unheated controls (HSP70B-NIS-MSCs + 37 
°C + NaCl). Damage to the thyroid as well as the salivary glands is a potential and well-
documented side effect of radioiodide therapy. In the present study, we used protocols similar 
to those used for patients that downregulate NIS expression in the thyroid gland (which is TSH 
regulated) by L-T4 pretreatment that helps to limit the damage to the thyroid and increases the 
circulating levels of radioiodide. Most of the iodide uptake in the cervical region seen on the 
images in Figure 3 is caused by iodide uptake in the salivary glands (that is not TSH regulated) 
which is anatomically close to the thyroid gland in mice and much bigger in comparison to the 
thyroid gland in humans [160]. Xerostomia is a recognized side effect of radioiodine treatment 
in some patients, but importantly, it is clinically manageable and has to be weighed against the 
benefit of effective tumor growth control. 
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One of the limitations of the present study is the somewhat heterogeneous tumoral response 
to hyperthermia. The therapy worked well in most of the animals, but in 33% of the animals the 
effect was reduced. This is believed to be due in part to the general model system applied here 
that used a water-based regional heat transfer method that has limitations for homogenous 
heat application in mouse flank tumors. This should be less of an issue in the clinic as the next 
generation hybrid magnetic resonance-guided high-intensity focused ultrasound now being 
used for tumor hyperthermia therapy allows a highly focused heating of the region with real-
time temperature mapping and energy deposition [99].  
As heat shows great chemo- and radiosensitizing qualities, hyperthermia has high potential as 
an adjuvant in multimodal treatment approaches, especially for sarcoma, melanoma, breast, 
or colon cancer [99]. The therapeutic effects of chemo- or radiotherapy can be enhanced by 
the administration of hyperthermia. Mild hyperthermia, at temperatures in the range of 39 to 
44 °C, is able to disturb the de novo synthesis of DNA by denaturation of synthetases and 
polymerases resulting in arrest of the cell cycle. It can furthermore induce apoptosis or 
necrosis, and interfere in a number of DNA repair mechanisms [98, 100]. Recently, there is 
also great interest in hyperthermia in the context of oncological immunotherapy, especially in 
regards to the therapy of metastases. In particularly, as hyperthermia can activate immune 
cells, initiate the release of exosomes and HSPs that present tumor antigens, enhance surface 
molecule expression on heated tumor cells, and thereby increase the immune sensitivity of 
tumors cells to the immune system. Lately, a phenomenon, called the abscopal effect, that 
was first discovered for local radiotherapy was now also detected for hyperthermia. It describes 
the findings that local tumor treatment is able to affect the growth of distant tumors and 
metastases and it is presumably mediated by the activation of the immune system [101]. 
In summary, our data demonstrate the potential of using a heat-inducible promoter (HSP70B) 
to drive NIS expression in MSCs, which allow an increased tumor-specific, temperature- and 
time-dependent NIS-mediated accumulation of radioiodide in heat-treated tumors. Application 
of 131I led to significantly reduced tumor growth and prolonged survival of animals receiving 
HSP70B-NIS-MSCs, 131I and hyperthermia. This proof-of-principle study has opened a new 
and exciting chapter on the way towards a future clinical application of genetically engineered 
MSCs in the context of NIS gene therapy with high translational relevance. 
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4.7 Abbreviations 
ANOVA: analysis of variances; CCL5: CC-chemokine ligand 5; cDNA: complementary DNA; 
CMV: cytomegalovirus; cpm: counts per minute; DNA: deoxyribonucleic acid; FBS: fetal bovine 
serum; HCC: hepatocellular carcinoma; HIF1α: hypoxia-inducible factor 1α; HSP: heat shock 
protein; HSV-TK: herpes simplex virus-thymidine kinase; ID: injected dose; i.p.: intraperitoneal;  
i.v.: intravenous; L-T4: L-thyroxine; MSCs: mesenchymal stem cells; mRNA: messenger 
ribonucleic acid; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NaCl: 
saline; NIS: sodium iodide symporter; PBS: phosphate-buffered saline; PET: positron-emission 
tomography; RANTES: regulated on activation, normal T cell expressed and secreted; RNA: 
ribonucleic acid; RT-PCR: real-time polymerase chain reaction; s.c.: subcutaneous; SEM: 
standard error of the mean; SG: salivary glands; TGFB1: transforming growth factor beta 1. 
 
4.8 Acknowledgements 
We are grateful to Dr Barbara von Ungern-Sternberg, Rosel Oos, and Dr Markus Strigl 
(Department of Nuclear Medicine, LMU Munich, Munich, Germany), and Jakob Allmann 
(Department of Nuclear Medicine, Klinikum rechts der Isar der Technischen Universität 
München, Munich, Germany) for their support with imaging and therapy studies. The authors 
thank Prof. Doris Mayr (Department of Pathology, LMU Munich, Munich, Germany) for 
preparation of paraffin-embedded slides. The authors owe special thanks to Prof. Julia 
Mayerle, Dr Ujjwal Mahajan and Dr Ivonne Regel (Department of Internal Medicine II, LMU 
Munich, Munich, Germany) for always allowing the use of their equipment and giving 
assistance. 
This work was supported by a grant from the Wilhelm Sander-Stiftung to C.S. and P.J.N. 
(2014.129.1), a grant from the Deutsche Forschungsgemeinschaft within the Collaborative 
Research Center SFB 824 to C.S. (project C8) as well as within the Priority Program 
SPP1629 to C.S. and P.J.N. 
This work was performed as partial fulfillment of the doctoral thesis of M. Tutter at the Faculty 
for Chemistry and Pharmacy of the LMU Munich. 
 
4.9 Competing Interests 
The authors have declared that no competing interest exists. 
  
Hyperthermia-inducible MSC-mediated NIS Gene Therapy 
62 
 
4.10 Supplement 
 
 
Supplementary Figure 1 Control groups for heat-induced MSC-mediated NIS gene therapy in vivo. Three 
days after systemic injections of HSP70B-NIS-MSCs, hyperthermia was administered to mice harboring HuH7 
xenograft tumors. 12 to 18 h later, saline was applied instead of 131I as control. This treatment cycle was repeated 
for a total of three times. Tumor growth (A) and overall survival (B) were evaluated for the treatment with 
HSP70B-NIS-MSCs, hyperthermia, and NaCl (HSP-NIS-MSCs + 41 °C + NaCl; n = 7), compared to a 
normothermic control group (HSP70B-NIS-MSCs + 37 °C + NaCl; n = 8), and saline control group (NaCl + 37 °C 
+ NaCl; n = 5). Results are expressed as mean ± SEM. 
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5. Summary 
The sodium iodide symporter (NIS) is the only human transporter protein that facilitates iodide 
uptake from the blood into the thyroid, as the first step of thyroid hormone synthesis. The ability 
of NIS to transport various radioisotopes provides the advantage of a combined diagnostic 
imaging/therapy (theranostic) strategy. In its role as reporter gene NIS allows expanded non-
invasive in vivo monitoring of MSC homing and engraftment at the tumor site in concert with 
molecular imaging of heat-inducible transgene expression by 123I-scintigraphy and 124I-, or 18F-
TFB-PET imaging. NIS has been used for almost 75 years for 131I treatment of thyroid cancer 
in the clinical setting, based on its role as therapy gene. Delivery of the theranostic NIS gene 
into non-thyroidal tumors opens the exciting possibility of transferring the well-established 
clinical protocol of radioiodine imaging and therapy to extra-thyroidal tumors. Previous studies 
convincingly demonstrated the successful transfer of the NIS gene to various cancer entities 
using viruses, polymers or mesenchymal stem cells (MSCs) as delivery vehicles. The excellent 
tumor homing ability of MSCs has made them attractive candidates as gene therapy vehicles. 
However, one of the major prerequisites for future clinical translation is the proof of a safe, 
tumor-selective, and effective transfer of the gene. With the aim to enhance the effectiveness 
and tumor-selectivity of MSC-mediated NIS gene therapy, in this thesis the combination with 
hyperthermia protocols was explored. While the intrinsic biologic effects of elevated 
temperature in cancer tissues is still not well understood, it has been well-demonstrated that 
increasing the temperature of the tumor (temperatures ranging from 39 °C to 42.5 °C) acts as 
an adjuvant, in multimodal cancer treatment schemes in clinical practice, such as radio- and 
chemotherapy as hyperthermia shows great chemo- and radiosensitizing qualities. 
One proposed effect of hyperthermia is the induction of the secretion of inflammatory 
chemokines and cytokines that are considered attractants for MSCs. The first aim of this thesis 
therefore was to study the potential of regional hyperthermia to enhance recruitment of MSCs 
to the tumor stroma. As a first step, the impact of hyperthermia on the hepatocellular carcinoma 
(HCC) cell line HuH7 and its capability to secrete the MSC-attracting cytokines was tested. 
The upregulation of diverse factors involved in MSC migration in response to mild hyperthermia 
(1 hour at 41 °C) was demonstrated in vitro and confirmed ex vivo by RT-PCR. A subsequent 
3D live cell migration assay confirmed the preferred movement of MSC towards supernatants 
derived from heat-treated HuH7 cancer cells as compared to unheated ones. This effect seen 
in vitro was further validated in vivo in an HCC xenograft tumor model. With the help of the NIS 
reporter gene system, the optimal time point and schedule of hyperthermia application for the 
highest stimulation of MSC migration after hyperthermia treatment was explored by 123I-
scintigraphy. Three days before the imaging, constitutively NIS expressing MSCs (CMV-NIS-
MSCs) were injected and hyperthermia treatment was conducted 6 hours, 24 hours, and 48 
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hours before or 24 hours and 48 hours after the MSC administration. Tumoral iodide 
accumulation was significantly enhanced in tumors that were heat-treated 24 hours post MSC-
injection compared to normothermic controls. The 123I-scintigraphy-based in vivo NIS imaging 
series was followed by evaluation of the therapeutic effectivity of 131I using the most effective 
hyperthermia/MSC/radioiodide application protocol evaluated in the previous imaging study. 
The optimal treatment scheme, hyperthermia 24 hours after MSC injection followed by 131I 
administration two days later, results in a prolonged survival and decreased tumor growth of 
animals receiving hyperthermia (41 °C) in addition to MSCs. Taken together, it was shown 
here for the first time that hyperthermia has the power to significantly boost MSC recruitment 
to the tumor stroma. 
The second aim of the thesis was to build on previous results with the potential of hyperthermia 
to maximize the efficacy of the MSC-mediated NIS gene therapy concept by adding a new 
dimension of precise control of NIS transgene expression. With the goal of gaining spatial and 
temporal control of NIS activation, MSCs were engineered to express the NIS gene under 
control of the heat-inducible HSP70B promoter. The ideal duration of hyperthermia application 
for maximal promoter activation and time point of maximal transgene expression after 
hyperthermia treatment was analyzed in vitro and in vivo utilizing the theranostic function of 
NIS, which permits the control of gene delivery efficiency by non-invasive imaging of functional 
tumoral NIS expression and therapeutic intervention by application of cytotoxic 131I. 
In vitro, HSP70B-NIS-MSCs were successfully characterized demonstrating low basal NIS 
activity with a high heat-induced functional NIS gene expression by iodide uptake assay, RT-
PCR, Western blot, and NIS-specific immunofluorescence staining. Following systemic 
application of HSP70B-NIS-MSCs, regional heat-treatment of subcutaneous HCC (HuH7) 
xenograft tumors resulted in increased tumor-specific, temperature- and time-dependent 
accumulation of iodide analyzed by 123I-scintigraphy that closely matched our in vitro results. 
The strongest iodine uptake in vivo was found 12 hours after hyperthermia treatment that was 
only slightly later than that seen in the cell culture studies (6 – 8 hours after promoter 
activation). Therapeutic 131I-application plus hyperthermia treatment led to prolonged survival 
with strongly reduced tumor growth with reduced blood vessel density and proliferation index, 
demonstrating the long-term antiangiogenic therapeutic efficacy of 131I as compared to all 
control groups. This translational study has opened a new and exciting chapter on the way 
towards a future clinical application of genetically engineered MSCs in the context of NIS gene 
therapy. 
In conclusion, the work presented in this thesis highlights the potential of combining regional 
hyperthermia with MSC-mediated NIS gene therapy from two different perspectives. On the 
one hand, hyperthermia showed a significant stimulatory effect on the migration rate of MSCs, 
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on the other hand, regional hyperthermia was successfully used to induce tumor-specific 
transgene expression in a spatial and temporal manner. Both strategies support the use of 
regional hyperthermia to optimize the efficacy of MSC-based NIS gene cancer therapy with 
great potential for successful future clinical translation.  
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